Page last updated: 2024-11-04

disulfiram

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3117
CHEMBL ID964
CHEBI ID4659
SCHEMBL ID27213
MeSH IDM0006600

Synonyms (315)

Synonym
S00294
MLS001076475
HMS3393M17
AB00051976-20
AB00051976-21
BRD-K32744045-001-05-6
thioperoxydicarbonic diamide, tetraethyl-
antaetil
disulfuram
tillram
thiuram disulfide, tetraethyl-
tuads, ethyl
hoca
stopaethyl
antabuse
ephorran
bis(n,n-diethylthiocarbamoyl) disulfide
refusal
abstinyl
tetraethylthiuran disulfide
tetraethylthioperoxydicarbonic diamide
n,n',n'-tetraethylthiuram disulfide
etabus
teturam
antabus
bonibal
anti-ethyl
antaethyl
contrapot
anticol
espenal
abstensil
anthethyl
antietil
exhorran
tetraethylthiram disulfide
ekagom teds
anteyl
krotenal
nsc25953
contralin
esperal
bis[(diethylamino)thioxomethyl] disulfide
averzan
thiuram e
stopetyl
antalcol
disulfan
antietanol
ethyl thiram
tetidis
tenurid
aversan
TTS ,
hocakrotenalnci-c02959
antetan
usaf b-33
teturamin
formamide,1'-dithiobis(n,n-diethylthio)-
ethyl thiurad
abstinil
tenutex
thireranide
thiuranide
tetradin
ethyl tuads
cronetal
ekagom tetds
tetradine
antetil
noxal
wln: 2n2 & yus & s 2
antiaethan
alk-aubs
1,n-diethylthioformamide]
antethyl
ethyldithiurame
antivitium
antaenyl
alcophobin
ethyl tuex
tetd
ethyl thiudad
nocbin
bis(diethylthiocarbamoyl) disulfide
antaethan
disetil
antikol
disulfide, bis(diethylthiocarbamoyl)
antadix
tatd
thioperoxydicarbonic diamide ([(h2n)c(s)]2s2), tetraethyl-
nsc-25953
tetraetil
ethyldithiourame
1,1'-dithiobis(n,n-diethylthioformamide)
MLS000069818 ,
CHEBI:4659 ,
1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane
tetraethylthiuram disulphide
n,n,n',n'-tetraethylthiuram disulfide
smr000059171
EU-0101164
D00131
disulfiram (jp17/usp/inn)
antabuse (tn)
SPECTRUM_001010
PRESTWICK3_000097
BSPBIO_001930
PRESTWICK_182
NCGC00016000-02
lopac-t-1132
cas-97-77-8
NCGC00016000-01
bis(diethylthiocarbamyl) disulfide
1,1'-dithiobis[n,n-diethylthioformamide]
diethylcarbamothioylsulfanyl n,n-diethylcarbamodithioate
SPECTRUM5_001590
PRESTWICK2_000097
LOPAC0_001164
BPBIO1_000060
BSPBIO_000054
tetraethylthiuram
exhoran
accel tet-r
soxinol tet
sanceler tet
dicupral
ekagom dtet
tetraethylthiuram sulfide
accel tet
sanceler tet-g
UPCMLD-DP090:001
inchi=1/c10h20n2s4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8h2,1-4h
AB00051976
bis(diethylthiocarbamoyl)disulphide
c10h20n2s4
hsdb 3317
nsc 25953
ent 27,340
bis((diethylamino)thioxomethyl)disulphide
nsc 190940
thioperoxydicarbonic diamide ((h2n)c(s))2s2, tetraethyl-
bis(n,n-diethylthiocarbamoyl)disulphide
dupont fungicide 4472
n,n,n',n'-tetraethylthiuram disulphide
tetraethylthiram disulphide
thioperoxydicarbonic diamide (((h2n)c(s))2s2), tetraethyl-
ro-sulfiram
ccris 582
dupon 4472
esperal [france]
disulfiramum [inn-latin]
formamide, 1,1'-dithiobis(n,n-diethylthio-
nci-c02959
einecs 202-607-8
disulfiramo [inn-spanish]
ai3-27340
bis((diethylamino)thioxomethyl) disulfide
C01692
tetraethylthiuram disulfide
disulfiram ,
97-77-8
MLS000758264
DB00822
cpd000059171 ,
UPCMLD-DP090
NCGC00094423-02
NCGC00094423-07
NCGC00094423-05
NCGC00094423-03
KBIO2_004058
KBIO3_001150
KBIOSS_001490
KBIO2_001490
KBIO2_006626
KBIOGR_000895
SPBIO_001993
PRESTWICK0_000097
SPBIO_001191
SPECTRUM4_000228
SPECTRUM2_001176
PRESTWICK1_000097
SPECTRUM3_000405
SPECTRUM1500262
NCGC00094423-01
NCGC00094423-06
tetraethylthiuram disulfide, >=97.0% (s)
NCGC00016000-03
HMS2090C18
HMS2091O22
HMS2051M17
T 1132 ,
B0479
NCGC00016000-09
STL069539
ora102
ora-102
CHEMBL964 ,
FT-0667720
HMS1568C16
HMS1920I16
1,1'',1'''',1''''''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane
n,n,n'',n''-tetraethylthiuram disulfide
1,1''-dithiobis(n,n-diethylthioformamide)
bdbm50058655
NCGC00016000-08
AKOS000120201
n,n-diethylcarbamodithioic acid [[diethylamino(sulfanylidene)methyl]thio] ester
A845750
HMS3263J09
HMS2095C16
tox21_400072
dtxcid101322
dtxsid1021322 ,
NCGC00254447-01
tox21_300403
MLS001423963
nsc-756748
pharmakon1600-01500262
nsc756748
tox21_110280
HMS2230K06
CCG-39549
NCGC00016000-05
NCGC00016000-14
NCGC00016000-15
NCGC00016000-10
NCGC00016000-04
NCGC00016000-07
NCGC00016000-11
NCGC00016000-12
NCGC00016000-06
NCGC00016000-13
perkacit tetd
ekaland tetd
ethyl tuads rodform
disulphuram
ancazide et
akrochem tetd
perkait tetd
ec 202-607-8
unii-tr3mlj1uai
thioperoxydicarbonic diamide (((h2n)c(s))2s2), n,n,n',n'-tetraethyl-
tr3mlj1uai ,
disulfiram [usp:inn:ban:jan]
FT-0631502
LP01164
S1680
n,n-diethyl[(diethylcarbamothioyl)disulfanyl]carbothioamide
HMS3371B21
gtpl7168
AB00051976-23
disulfiram [hsdb]
disulfiram [mi]
disulfiram [orange book]
disulfiram [jan]
disulfiram [who-dd]
disulfiram [ep monograph]
disulfiram [mart.]
thioperoxydicarbonic diamide ((h2n)c(s))(sub 2) s(sub 2), tetraethyl-
disulfiram [vandf]
disulfiram [ep impurity]
bis(diethylthiocarbamoyl) disulphide
disulfiram [inn]
disulfiram [usp monograph]
disulfiram [iarc]
tetraethylthioperoxydicarbonic diamide ((((c(sub 2)h(sub 5))(sub 2)n)c(s))(sub 2)s(sub 2))
DL-379
HY-B0240
NC00063
1,1',1'',1'''-{disulfanediylbis[(thioxomethylene)-nitrilo]}tetraethane
SCHEMBL27213
tox21_110280_1
NCGC00016000-18
HS-0057
tox21_501164
NCGC00261849-01
tetraethyl thiuram disulfide
bis-(diethyl-thiocarbamyl)-disulfide
Q-201812
bis(diethylthiocarbamyoyl)disulfide
tetraethyldithiuram disulfide
formamide, 1,1'-dithiobis(n,n-diethylthio)-
thioperoxydicarbonic diamide ([(h2n)c(s)]2s2), n,n,n',n'-tetraethyl-
HB1119
AB00051976_25
OPERA_ID_224
AB00051976_22
mfcd00009048
disulfiram, united states pharmacopeia (usp) reference standard
disulfiram, european pharmacopoeia (ep) reference standard
HMS3655I19
AT13284
disulfiram, pharmaceutical secondary standard; certified reference material
SR-01000076145-1
SR-01000076145-5
SR-01000076145-8
sr-01000076145
SBI-0051131.P004
HMS3712C16
disulfiram, british pharmacopoeia (bp) reference standard
SW196492-4
tetraethylthiuram disulfide;tetd
BCP07331
Q409665
disulfiram (antabuse) ,
BRD-K32744045-001-17-1
HMS3867H13
SDCCGSBI-0051131.P005
NCGC00016000-29
nsc800739
nsc-800739
EN300-19458
Z104473910

Research Excerpts

Overview

Disulfiram is an FDA-approved drug used to treat chronic alcoholism. It is a potent anti-inflammatory agent and an inhibitor of the viral proteases. It has been confirmed to show anticancer bioactivity after chelating with Cu.

ExcerptReferenceRelevance
"Disulfiram is an FDA-approved drug used to treat chronic alcoholism. "( Development of new disulfiram analogues as ALDH1a1-selective inhibitors.
Omran, Z, 2021
)
2.39
"Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs."( Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor.
Gean, PW; Lin, MX; Liu, CC; Sze, CI; Wu, CL, 2021
)
2.79
"Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases."( Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
Bell, S; Brophy, M; Do, N; Dubreuil, M; Fillmore, N; La, J; Lieberman, J; Mehta, G; Nguyen, V; Sander, C; Shen, C; Strymish, J; Wu, H, 2021
)
2.79
"Disulfiram (DSF) is a clinical antialcoholism drug that has been confirmed to show anticancer bioactivity after chelating with Cu"( Smart Tumor Microenvironment-Responsive Nano-Prodrug for Disulfiram Toxification In Situ and the Exploration of Lethal Mechanisms in Cells.
Jin, Y; Ma, K; Qi, G; Qu, X; Wang, B; Zhang, Y, 2022
)
2.41
"Disulfiram (DSF) is an FDA-approved treatment for chronic alcohol addiction, and its cardio-protection is gradually discovered in recent years."( Disulfiram inhibits oxidative stress and NLRP3 inflammasome activation to prevent LPS-induced cardiac injury.
Huang, J; Li, W; Peng, Z; Wei, S; Xiao, Z; Zhang, B, 2022
)
2.89
"Disulfiram (Antabuse®) is an alcohol use disorder medication that exhibits antifungal activity against Candida species. "( Effect of copper on the antifungal activity of disulfiram (Antabuse®) in fluconazole-resistant Candida strains.
Carreon, H; Long, TE; Rice, C; Shanholtzer, CN; Watson, K, 2022
)
2.42
"Disulfiram (DSF) is an approved drug for the treatment of alcohol dependence. "( Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc.
Du, C; Du, X; Guan, X; Li, B; Liu, Y; Wang, M; Xu, Z; Zheng, Z, 2022
)
3.61
"Disulfiram (DSF) is an anti-alcoholism medication with superior antitumor activity and clinical safety; its antitumor mechanisms in gastric cancer (GC) have not been fully explored. "( Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways.
Chen, Y; Du, C; Fu, F; Guan, X; Li, B; Liu, Y; Wang, M; Wang, N; Xu, Z; Zheng, Z, 2022
)
3.61
"Disulfiram (DSF) is a drug used to clinically control alcoholism that has recently been shown to be cytotoxic for multiple cancers."( Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway.
Chen, C; Chen, Z; Huang, Y; Li, Y; Liu, X; Liu, Z; Nie, D; Sui, S; Tan, J; Wang, X; Yu, X; Yu, Z; Zeng, C; Zhong, M, 2022
)
1.76
"Disulfiram (DSF) is an FDA-approved medicine for the treatment of alcoholism; however, it was later revealed to have anticancer properties."( Repurposing Disulfiram as a Chemo-Therapeutic Sensitizer: Molecular Targets and Mechanisms.
Hong, B; Nie, J; Sun, F; Wang, H, 2022
)
1.82
"Disulfiram (DSF), which is an inhibitor of aldehyde dehydrogenase (ALDH) and approved by the FDA for the treatment of alcoholism previously, has been repurposed for use as a cancer treatment because of its potent effect in preclinical studies. "( Transcription factor p8 regulates autophagy in response to disulfiram via PI3K/mTOR/p70S6K signaling pathway in pancreatic cancer cells.
Chang, X; Feng, Z; Gao, J; Li, X; Liu, F; Wang, Y; Xiao, L; Yao, Z; Zhang, X, 2022
)
2.41
"Disulfiram is a well-known alcohol abuse drug, and recent studies have shown its ability to mitigate pyroptosis in mouse macrophages."( Disulfiram ameliorates ischemia/reperfusion-induced acute kidney injury by suppressing the caspase-11-GSDMD pathway.
Cai, Q; Guo, S; Jiao, X; Li, Y; Sun, Z; Wu, H; Xu, S; Yu, X, 2022
)
2.89
"Disulfiram (DSF) is an approved drug for alcohol abuse."( Folic acid-modified disulfiram/Zn-IRMOF3 nanoparticles for oral cancer therapy by inhibiting ALDH1A1+ cancer stem cells.
Bu, W; Chen, M; Chen, X; Cui, J; Li, W; Li, X; Liu, C; Liu, J; Meng, L; Sun, H; Wang, J, 2022
)
1.77
"Disulfiram (DSF) is an FDA-proved drug with potential therapeutic effects on inflammatory diseases."( Disulfiram reduces the severity of mouse acute pancreatitis by inhibiting RIPK1-dependent acinar cell necrosis.
Dai, C; Huang, KL; Huang, QY; Lin, ZH; Liu, YY; Shen, Y; Yu, XY; Yuan, L; Zhang, QY; Zhang, R, 2023
)
3.07
"Disulfiram (DS) is an anti-alcoholism drug capable of acting against important and hard-to-treat cancers. "( High-capacity glycol chitosan-based nanoemulsion for efficient delivery of disulfiram.
Abd Kadir, E; Schätzlein, AG; Uchegbu, IF, 2023
)
2.58
"Disulfiram (DSF) is a drug used for treatment of alcoholism that has also displayed promising anti-cancer activity. "( Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
Albers, AE; Guo, F; Kaufmann, AM; Kulbe, H; Sehouli, J; Yang, Z, 2019
)
2.2
"Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. "( Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells.
Arpicco, S; Bincoletto, V; Gazzano, E; Lollo, G; Riganti, C; Rolando, B; Rolle, F; Stella, B, 2020
)
2.33
"Disulfiram (DSF) is an FDA approved anti-alcoholism drug in use for more than 60 years. "( Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways.
Dai, Y; Feng, X; Jiang, W; Jiang, Y; Liu, X; Ni, Y; Wang, Y; Xing, X; Xu, Y; Zheng, C; Zhou, Q, 2020
)
3.44
"Disulfiram (DSF) is a thiuram derivative that was developed to treat alcoholism but was also found to have antitumor activity. "( The combination of disulfiram and copper for cancer treatment.
Chen, ZS; Cui, W; Li, H; Wang, J; Wang, L; Wu, C, 2020
)
2.33
"Disulfiram (DSF) is an old alcohol-aversion drug that has anti-tumor activities against diverse cancer types such as GBM in preclinical studies, especially when it is combined with cupper ion (Cu)."( Therapeutic effect of disulfiram inclusion complex embedded in hydroxypropyl-β-cyclodextrin on intracranial glioma-bearing male rats via intranasal route.
Li, C; Ma, D; Ma, L; Ma, W; Qu, Y; Sun, X; Xu, Z; Zhao, Z; Zhou, Y, 2021
)
1.66
"Disulfiram is an adjunct in the treatment of alcohol use disorders, but case reports indicate that disulfiram ethanol reactions are not always recognized in the emergency department. "( Recognition of a disulfiram ethanol reaction in the emergency department is not always straightforward.
Buylaert, W; Chys, S; De Paepe, P; Desmet, T; Huys, L; Segher, K; Steen, E, 2020
)
2.34
"Disulfiram is a promising repurposed drug that, combining with radiation and chemotherapy, exhibits effective anticancer activities in several preclinical models. "( Disulfiram and 6-Thioguanine synergistically inhibit the enzymatic activities of USP2 and USP21.
Chen, WY; Cheng, SC; Chu, HF; Kuan, Y; Lin, HC; Lin, TH; Pan, HC; Sun, CY, 2021
)
3.51
"Disulfiram (DSF) is a well-known anti-alcohol agent that inhibits aldehyde dehydrogenase and results in extreme 'hangover' symptoms when consumed with alcohol. "( Advantages and disadvantages of disulfiram coadministered with popular addictive substances.
Kleczkowska, P; Sulejczak, D; Zaremba, M, 2021
)
2.35
"Disulfiram is a drug used to support the treatment of chronic alcoholism and was found to be effective against diverse cancer types in preclinical studies."( Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation.
Anderson, J; Cantilena, S; de Boer, J; Hargrave, D; Meier, S; Michod, D; Niklison Chirou, MV; Salomoni, P, 2021
)
1.67
"Disulfiram is a dehydrogenase inhibitor used to treat alcoholism and has been suggested as a proteasome inhibitor."( Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome.
Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Nguyen, V; Tong, S; Ye, L, 2018
)
2.64
"Disulfiram (DSF) is a drug used clinically for alcoholism treatment that has displayed promising anti-cancer activity in vitro and in cancer xenografts in breast cancer."( Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Albers, AE; Guo, F; Kaufmann, AM; Sehouli, J; Yang, Z, 2019
)
2.68
"Disulfiram is a potential cocaine addiction pharmacotherapy. "( ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.
Hamon, SC; Harding, MJ; Kosten, TR; Nielsen, DA; Spellicy, CJ, 2013
)
2.11
"Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production. "( Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.
Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Nielsen, DA; Shorter, D, 2013
)
2.08
"Disulfiram is an aldehyde dehydrogenase inhibitor that was used to treat alcoholism and showed anticancer activity, but its anticancer mechanism remains unclear. "( Disulfiram deregulates HIF-α subunits and blunts tumor adaptation to hypoxia in hepatoma cells.
Cho, CH; Cho, K; Choi, YJ; Kim, MS; Park, HJ; Yun, JH, 2013
)
3.28
"Disulfiram is an alcohol-deterring agent with few rare serious adverse effects, usually dose-related, reversible, and more frequent with comorbid alcohol and nicotine dependence. "( Disulfiram-induced combined irreversible anterior ischemic optic neuropathy and reversible peripheral neuropathy: a prospective case report and review of the literature.
Bairy, BK; Kulkarni, RR; Pradeep, AV, 2013
)
3.28
"Disulfiram is a viable treatment option for the high-risk population studied here. "( Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment.
Heilmann, M; Lieb, B; Scherbaum, N; Specka, M,
)
2.03
"Disulfiram is an inexpensive and safe drug; if its addition to chemotherapy could be shown to prolong survival, an effective regimen could be established and used widely, even in resource-poor countries."( A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Baron, A; Gotfried, M; Hamamreh, Y; Nechushtan, H; Nidal, S; Nisman, B; Peretz, T; Peylan-Ramu, N; Shalev, YI, 2015
)
1.4
"Disulfiram proved to be a well-tolerated medication as part of multimodal therapy of alcohol dependency. "( [Disulfiram in outpatient treatment of alcohol dependency].
Brieger, P; Hochsattel, K, 2016
)
2.79
"Disulfiram (DSF) is a dimer of diethyldithiocarbamate (DDC) that we previously added to a solution of 2-hydroxypropyl-β-cyclodextrin (DSF solution). "( An Ophthalmic Formulation of Disulfiram Nanoparticles Prolongs Drug Residence Time in Lens.
Ito, Y; Mano, Y; Nagai, N, 2016
)
2.17
"Disulfiram (DSF) is an approved drug for the treatment of alcohol dependence, but has also been shown to kill TNBC cells in a copper (Cu)-dependent manner."( Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
An, H; Cho, TM; Cho, Y; Kim, JY; Kim, YJ; Lee, N; Oh, E; Seo, JH; Sung, D, 2017
)
2.62
"Disulfiram is a readily available and inexpensive substance whose adverse effects are negligible, compared to classical cancerostatics."( The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek, B; Dvorak, Z, 2008
)
1.31
"Disulfiram is a non-nucleoside DNMT1 inhibitor that can reduce global (5me)C content, reactivate epigenetically silenced genes, and significantly inhibit growth in prostate cancer cell lines."( Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
Brennen, WN; Britton, J; Carducci, MA; Haffner, MC; Kachhap, SK; Lee, BH; Lin, J; Liu, JO; Nelson, WG; Shim, JS; Yegnasubramanian, S; Zhang, Y, 2011
)
3.25
"Disulfiram is a FDA approved drug for the treatment of alcoholism and available for clinical use since over 5 decades. "( Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies.
Buac, D; Kona, FR; M Burger, A, 2011
)
3.25
"Disulfiram is a relatively old molecule, which today remains marginal in the treatment of alcoholics diseases. "( [Disulfiram and addiction: reminders and new perspectives of use].
Brousse, G; Charpeaud, T; Geneste, J; Llorca, PM; Schmidt, J,
)
2.48
"Disulfiram seems to be a valuable drug for the treatment of cocaine dependency. "( [Disulfiram as a treatment for cocaine dependency].
De Mulder, I; Dom, G, 2012
)
2.73
"Disulfiram (DSF) is an aldehyde dehydrogenase inhibitor currently used for the treatment of alcoholism. "( Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
Adamo, L; Amato, G; Anastasi, G; Buccheri, S; Cavalli, M; Chiarenza, A; Conticello, C; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gulisano, M; Lombardo, L; Martinetti, D; Parrinello, N, 2012
)
3.26
"Disulfiram is a cocaine pharmacotherapy that may act through increasing serotonin, benefiting patients with genetically low serotonin transporter levels (5-HTTLPR, S' allele carriers) and low serotonin synthesis (TPH2, A allele carriers). "( Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study.
Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Nielsen, DA, 2012
)
2.06
"Disulfiram is a substance often used to treat alcohol dependency. "( [A patient with a life-threatening disulfiram-ethanol reaction].
de Vries, F; Havenith, T; Hulsewe-Evers, HP; Hurkens, KP; Tummers-de Lind van Wijngaarden, RF, 2013
)
2.11
"Disulfiram is a drug used since 1940 in the treatment of alcohol dependence. "( [Anterior myocardial infarction in a chronic alcoholic man on disulfiram therapy: a case report].
Brun, F; Cassin, M; Nicolosi, GL; Nucifora, G, 2004
)
2.01
"Disulfiram is a thiuram disulfide with potent cancer preventive activity in in vivo models of chemical carcinogenesis."( PKC sulfhydryl targeting by disulfiram produces divergent isozymic regulatory responses that accord with the cancer preventive activity of the thiuram disulfide.
Chu, F; O'Brian, CA,
)
1.15
"Disulfiram is an inhibitor of the enzyme aldehyde dehydrogenase and acts as an alcohol-deterrent drug."( Preclinical and clinical pharmacology of alcohol dependence.
Quertemont, E; Tambour, S, 2007
)
1.06
"Disulfiram is a safe and well-tolerated drug that may be useful for other radioligands that undergo defluorination via CYP2E1."( Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain.
Collins, J; Fujita, M; Hong, J; Innis, RB; Liow, JS; Pike, VW; Ryu, YH; Sangare, J; Tipre, D; Zoghbi, S, 2007
)
2.5
"Disulfiram acts as an ACD blocker."( Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?
Barber, TJ; Mackie, NE; Marett, B; Portsmouth, S; Waldron, S; Weston, R; Winston, A, 2007
)
1.62
"Disulfiram was found to be an in vivo and in vitro inhibitor of the enzymes obtained from these brain regions."( Distribution and properties of aldehyde dehydrogenase in regions of rat brain.
Ardelt, B; Weiner, H, 1984
)
0.99
"Disulfirame is a rare cause of peripheral neuropathy in subjects with chronic alcoholism. "( [Peripheral neuropathies caused by disulfiram].
Bregigeon, M; Brosset, C; Dano, P; Tammam, D, 1996
)
2.01
"Disulfiram is an aldehyde dehydrogenase inhibitor that is widely used as an adjunctive agent in the treatment of patients with severe chronic alcoholism. "( Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism.
Adams, KM; Gilman, S; Heumann, M; Hill, E; Johnson-Greene, D; Junck, L; Kluin, KJ; Koeppe, RA; Martorello, S, 1996
)
2.13
"Disulfiram was found to be a potent competitive reversible inhibitor with KEO,I values at pH 7.0 and 10.0 of 50 microM and 30 microM, respectively."( The effects of disulfiram and related compounds on equine hepatic alcohol dehydrogenase.
Langeland, BT; McKinley-McKee, JS, 1997
)
1.37
"Disulfiram (DSF) is a mechanism-based inhibitor of cytochrome P-450 2E1 (CYP2E1), resulting in loss of CYP2E1 protein and activity, which may be useful in preventing CYP2E1-mediated xenobiotic toxicity. "( Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.
Emery, MG; Jubert, C; Kharasch, ED; Thummel, KE, 1999
)
1.95
"Disulfiram is a widely used drug to treat alcoholism due to its capacity to inhibit the metabolism of acetaldehyde; however, its genotoxic potential is not well known. "( Sister-chromatid exchanges induced by disulfiram in bone marrow and spermatogonial cells of mice treated in vivo.
Chamorro, G; Madrigal-Bujaidar, E; Martínez, AL; Mendiola, MT; Morales-Ramirez, P; Velazquez-Guadarrama, N, 1999
)
2.02
"Disulfiram (DSF) is a drug used in aversion therapy to treat alcoholics and acts by inhibiting mitochondrial low-K(m) aldehyde dehydrogenase. "( Disulfiram generates a stable N,N-diethylcarbamoyl adduct on Cys-125 of rat hemoglobin beta-chains in vivo.
Amarnath, V; Erve, JC; Jensen, ON; Valentine, HS; Valentine, WM, 2000
)
3.19
"Disulfiram is a dithiocarbamate drug used for alcohol aversion therapy that produces a distal sensorimotor peripheral neuropathy in certain individuals. "( Disulfiram produces a non-carbon disulfide-dependent schwannopathy in the rat.
Erve, JC; Tonkin, EG; Valentine, WM, 2000
)
3.19
"Disulfiram is an effective therapeutic agent in the treatment of chronic alcoholism as long as certain conditions are maintained; the patient realises that he is ill, the patient is motivated to be treated and that alcohol withdrawal be maintained chiefly during the first year where there is periodic uneasiness. "( [Evaluation of disulfiram treatment in chronic alcoholism].
Acke, J, 1975
)
2.05
"Disulfiram is a drug used in the treatment of chronic alcoholism in man. "( Method for the detection of diethylamine, a metabolite of disulfiram, in urine.
Fuller, RK; Hejduk, LJ; Neiderhiser, DH; Roth, HP, 1976
)
1.94
"Disulfiram is an irreversible ALDH inhibitor when administered in vivo."( The pharmacology and toxicology of disulfiram and its metabolites.
Petersen, EN, 1992
)
1.28
"Disulfiram is a potent antioxidant that prevented the peroxidation of microsomal phospholipids induced by ADP/Fe3+ at concentrations as low as 1 microM. "( The inhibition of lipid peroxidation by disulfiram prevents the killing of cultured hepatocytes by allyl alcohol, tert-butyl hydroperoxide, hydrogen peroxide and diethyl maleate.
Farber, JL; Kyle, ME; Serroni, A, 1989
)
1.99
"Disulfiram appears to be a useful adjunct for drug abusers with serious alcohol problems."( Brief effective treatment strategies: pharmacological therapy for opiate addicts.
Kleber, HD, 1985
)
0.99
"Disulfiram toxicity is a well-recognized cause of peripheral neuropathy and encephalopathy, usually developing within a few months of the start of therapy. "( Reversible, late-onset disulfiram-induced neuropathy and encephalopathy.
Ashby, P; Bilbao, J; Borrett, D; Carlen, P, 1985
)
2.02
"Disulfiram is a potent alcohol-sensitizing drug, the effectiveness of which remains unproven in the treatment of alcoholism after 40 years of use. "( The clinical use of disulfiram (Antabuse): a review.
Banys, P,
)
1.9

Effects

Disulfiram (DSF) has a long history of being used as a first-line promising therapy for treatment of alcoholism in human. It has a prolonged inhibitory effect; this effect is enhanced and extended when it is combined with acetaldehyde (400 mg/kg)

Disulfiram has been used as an adjunct to the treatment of chronic alcoholism since 1948. The drug has been shown to decrease the incidence of arrhythmias in rabbits exposed to trichloroethylene.

ExcerptReferenceRelevance
"Disulfiram (DSF) has a long history of being used as a first-line promising therapy for treatment of alcoholism in human. "( Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.
Ahmad, MM; Ahsan, A; Ahsan, HM; Aquib, M; Baig, MMFA; Farooq, MA; Hussain, Z; Jiajie, J; Khan, DH; Wande, DP; Wang, B, 2019
)
2.23
"Disulfiram (200 mg/kg) has a prolonged inhibitory effect; this effect is enhanced and extended when the disulfiram is combined with acetaldehyde (400 mg/kg)."( Inhibition of the metabolism of ethyl carbamate by acetaldehyde.
Hurst, HE; Kemper, R; Kurata, N; Waddell, WJ,
)
0.85
"Disulfiram (DSF) has been proven safe and shows the promising antitumor effect in preclinical studies. "( Quantitative proteomics analysis reveals novel insights into mechanisms of action of disulfiram (DSF).
Chen, Y; Chen, Z; Hu, F; Liu, C; Wu, Y; Xu, R; Zhang, T; Zheng, P, 2022
)
2.39
"Disulfiram at 20 μM has no significant cytotoxic effect and does not affect cell migration. "( Disulfiram inhibits IL-1β secretion and inflammatory cells recruitment in Aspergillus fumigatus keratitis.
Che, C; Chen, X; Cong, P; Han, L; Lu, D; Sun, X; Wang, L; Yan, H; Yang, H, 2022
)
3.61
"Oral disulfiram (DSF) has been used clinically for alcohol dependence and recently has been found to have antitumor activity. "( Effects and Mode of Action of Oleic Acid and Tween 80 on Skin Permeation of Disulfiram.
Chiba, Y; Ikeuchi-Takahashi, Y; Obata, Y; Ohnari, H; Saitoh, H; Takami, K, 2023
)
1.65
"Disulfiram has demonstrated broad antitumoral effect in several preclinical studies. "( Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
Bartek, J; Carstam, L; Gulati, S; Hylin, S; Jakola, AS; Kinhult, S; Lindskog, M; Löfgren, D; Magelssen, H; Mudaisi, M; Rashid, HB; Salvesen, Ø; Solheim, O; Solheim, TS; Strandéus, M; Werlenius, K, 2023
)
2.76
"Disulfiram has long been used in the treatment of alcohol dependency and multiple clinical trials to evaluate its clinical value in oncology are ongoing."( Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET.
Andújar-Sánchez, M; Arampatzis, S; Bartek, J; Bartkova, J; Björkman, A; Espinoza, JA; Fernandez-Capetillo, O; Kanellis, DC; Kosar, M; Lemmens, B; Li, X; Lindström, MS; Mistrik, M; Skrott, Z; Zisi, A, 2023
)
1.84
"Disulfiram (DSF) has proven to be a promising anti-tumor drug in preclinical studies. "( Disulfiram suppresses epithelial-mesenchymal transition (EMT), migration and invasion in cervical cancer through the HSP90A/NDRG1 pathway.
Hu, F; Wang, Y; Wu, Y; Zheng, P, 2023
)
3.8
"Disulfiram has been used in the treatment of alcoholism and exhibits an anti-tumor effect. "( Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Hong, JH; Hwang, S; Shin, DM, 2019
)
2.22
"Disulfiram (DSF) has a long history of being used as a first-line promising therapy for treatment of alcoholism in human. "( Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.
Ahmad, MM; Ahsan, A; Ahsan, HM; Aquib, M; Baig, MMFA; Farooq, MA; Hussain, Z; Jiajie, J; Khan, DH; Wande, DP; Wang, B, 2019
)
2.23
"Disulfiram (DSF) has exhibited potent autophagy inducing activity in multiple studies."( Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy.
Chowdhury, R; Roy, A; Sharma, S; Swetha, KL, 2020
)
2.72
"Disulfiram has been repurposed as a potential candidate to suppress various cancers. "( Repurposing disulfiram to induce OSCC cell death by cristae dysfunction promoted autophagy.
Cai, LY; Chen, QM; Ji, N; Jiang, H; Shen, YQ; Wang, Z; Zeng, X; Zhou, Y, 2021
)
2.44
"Disulfiram (DSF) has shown its effectiveness against GBM, especially with copper ion (Cu)."( Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy.
Iqbal, S; Li, A; Li, C; Ma, D; Ma, L; Ma, W; Qu, Y; Sun, X; Xu, Z; Zhao, Z; Zheng, D, 2021
)
1.64
"Disulfiram has been widely used for over six decades in the treatment of alcohol dependence, as an aversive therapeutic agent. "( Disulfiram-induced epileptic seizures.
Mendes, MA; Nogueira, V; Pereira, I; Teixeira, J, 2021
)
3.51
"Disulfiram (DSF) has copper (Cu)-dependent anticancer properties in vitro and in vivo."( Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Li, TY; Li, Y; Liu, S; Wang, LH; Wang, YT; Wu, CF; Yang, JY; Yuan, XZ; Zhang, HT; Zhou, WL, 2018
)
2.64
"Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models. "( Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018
)
2.15
"Disulfiram has also been shown to inhibit the proteasomes, DNA topoisomerases, DNA methyltransferase, glutathione S-transferase P1, and O6- methylguanine DNA methyltransferase, a DNA repair protein highly expressed in brain tumors."( Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents.
Dou, QP; Ekinci, E; Khan, R; Rohondia, S, 2019
)
1.61
"Disulfiram has been beneficial in treating cocaine addiction in several studies. "( Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction.
Hamon, SC; Harding, MJ; Kampangkaew, JP; Kosten, TR; Nielsen, DA; Nielsen, EM; Spellicy, CJ; Ye, A, 2019
)
2.18
"Disulfiram has been used for several decades in the treatment of alcoholism. "( The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells.
Babich, JW; Boyd, M; Mairs, RJ; Rae, C; Sorensen, A; Tesson, M, 2013
)
2.15
"Disulfiram has differential effects on cocaine and methadone metabolism, but its impact on methadone- or cocaine-induced changes in QTc interval is unclear."( Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients.
Atkinson, TS; Mancino, M; Oliveto, A; Sanders, N,
)
1.24
"Disulfiram (DSF) has been used to treat alcoholism for many years and it has been suggested to play a key role in combatting many kinds of tumors. "( A novel UPLC-ESI-MS/MS method for the quantitation of disulfiram, its role in stabilized plasma and its application.
Chen, X; Jiang, Y; Jing, G; Tang, X; Tang, Y; Yang, D; Zhang, L; Zhang, Y, 2013
)
2.08
"Disulfiram (DSF), which has multi-targeted anti-tumor activity, was encapsulated into redox-sensitive shell crosslinked micelles to achieve intracellular targeted delivery and finally inhibit tumor growth and metastasis."( Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram.
Duan, X; Li, Y; Mao, S; Xiao, J; Yin, Q; Yu, H; Zhang, Z, 2014
)
1.33
"Disulfiram has shown promise as a pharmacotherapy for cocaine dependence in clinical settings, although it has many targets, and the behavioral and molecular mechanisms underlying its efficacy are unclear. "( Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.
Cooper, DA; Howell, LL; Kimmel, HL; Manvich, DF; Schmidt, KT; Weinshenker, D, 2014
)
1.85
"Disulfiram has demonstrated antineoplastic action against prostate, breast and lung cancer."( Development of disulfiram-loaded vaginal rings for the localised treatment of cervical cancer.
Boyd, P; Major, I; McConville, C; Wang, W, 2014
)
1.48
"Disulfiram has primarily been used to treat alcoholism."( Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.
Melby, PC; Peniche, AG; Renslo, AR; Travi, BL, 2015
)
1.43
"Disulfiram has been successfully used to suppress hepatic metastases originating from ocular melanoma."( The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek, B; Dvorak, Z, 2008
)
1.31
"Disulfiram has demonstrated efficacy in six randomized clinical trials for the treatment of cocaine dependence, but is rarely used in clinical settings because of safety concerns."( The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice.
Lechner, W; Malcolm, R; Olive, MF, 2008
)
2.15
"Disulfiram has been used for decades to treat alcoholism. "( Mechanisms and kinetics of human arylamine N-acetyltransferase 1 inhibition by disulfiram.
Dairou, J; Dupret, JM; Malka, F; Ragunathan, N; Rodrigues-Lima, F, 2009
)
2.02
"Disulfiram has also been shown to deter cocaine use, even in the absence of an interaction with alcohol, indicating the existence of an ALDH-independent therapeutic mechanism."( Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylase.
Cooper, DA; Edwards, GL; Freeman, KG; Gaval-Cruz, M; Holmes, PV; Iuvone, PM; Lyle, MA; Ogbonmwan, YE; Pozdeyev, N; Schank, JR; Schroeder, JP; Weinshenker, D, 2010
)
2.52
"Disulfiram has been shown to be efficacious and safe in the treatment of alcohol relapse prevention. "( Urinary ethylglucuronide assessment in patients treated with disulfiram: a tool to improve verification of abstention and safety.
Grosshans, M; Hermann, D; Kiefer, F; Koopmann, A; Mann, K; Mutschler, J,
)
1.82
"Disulfiram has been used extensively for alcohol abuse and may have a role in treatment for cocaine addiction. "( Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry.
Hochreiter, J; Lapham, J; Ma, Q; McCance-Katz, EF; Morse, GD, 2012
)
3.26
"Disulfiram has been an effective cocaine addiction pharmacotherapy, and one of its possible mechanisms of efficacy is through copper chelation and inhibition of an enzyme involved in catecholamine metabolism, dopamine β-hydroxylase (DβH), which converts dopamine to norepinephrine. "( Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.
Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Lappalainen, J; Nielsen, DA; Wu, G, 2013
)
2.08
"Disulfiram has emerged as a promising treatment for cocaine dependence, but it has not yet been evaluated in general populations of cocaine users."( Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.
Ball, SA; Carroll, KM; Fenton, LR; Frankforter, TL; Nich, C; Rounsaville, BJ; Shi, J, 2004
)
2.15
"Disulfiram has been used as a popular adjunct in programs for alcohol rehabilitation. "( Liver transplantation for disulfiram-induced fulminant hepatic failure.
LaBrecque, DR; Layden, TJ; Mitros, FA; Mohanty, SR, 2004
)
2.07
"Disulfiram has been shown to be most effective for patients who believe in its efficacy and remain compliant with the treatment."( [The pharmacologic treatment of the alcohol dependence].
Baltieri, DA; Castro, LA, 2004
)
1.04
"Disulfiram has been studied as a treatment for cocaine dependence. "( Disulfiram effects on responses to intravenous cocaine administration.
Baker, JR; Jatlow, P; McCance-Katz, EF, 2007
)
3.23
"Disulfiram has been used since the late 1940s to treat chronic alcoholism. "( [Optic neuropathy while taking disulfiram].
Bessero, AC; Borruat, FX; Daeppen, JB, 2006
)
2.06
"Disulfiram has been used for alcohol aversion therapy."( Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression.
Chang, YC; Cho, HJ; Cho, YS; Choe, JY; Choi, MR; Han, SM; Lee, KG; Lee, TS; Lee, YS; Moon, YS; Park, JB; Park, KK; Park, NG; Park, YY; Sin, DI; Yeo, JH, 2007
)
2.5
"Disulfiram has shown promise in several clinical trials for cocaine addiction, but its potential utility in the treatment of amphetamine addiction has not been examined. "( Disulfiram enhances subjective effects of dextroamphetamine in humans.
Hill, K; Kosten, T; Poling, J; Sewell, A; Sofuoglu, M; Waters, A, 2008
)
3.23
"Disulfiram has been used as an adjunct to the treatment of chronic alcoholism since 1948. "( Disulfiram-induced hepatitis--report of a case and review of the literature.
Nässberger, L, 1984
)
3.15
"Disulfiram has been shown to decrease the incidence of arrhythmias in rabbits exposed to trichloroethylene. "( Antiarrhythmic effect of disulfiram in various cardiotoxic models.
Carlson, GP; Fossa, AA, 1983
)
2.01
"Disulfiram has been used safely in millions of people since 1948, and we have only few cases reports of severe toxicity."( [Disulfiram (Esperal) toxicity. Apropos of 3 original cases].
Boisson, D; Charles, N; Dupuy, O; Flechaire, A; Flocard, F; Rode, G; Vial, C, 1995
)
1.92
"Disulfiram has been used to treat alcoholism in adults since 1948, but there are no known reports of disulfiram treatment in minors."( Disulfiram for alcohol use disorders in adolescents.
Donahue, JE; Goldstein, MR; Myers, WC, 1994
)
2.45
"Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse. "( First trimester disulfiram exposure: report of two cases.
Helmbrecht, GD; Hoskins, IA, 1993
)
2.07
"Disulfiram (DSF) has found extensive use in the aversion therapy treatment of recovering alcoholics. "( Overview--in vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites.
Lipsky, JJ; Naylor, S; Shen, ML, 2001
)
2
"Disulfiram (DSF) has found extensive use in the aversion therapy treatment of recovering alcoholics. "( In vivo inhibition of aldehyde dehydrogenase by disulfiram.
Lipsky, JJ; Naylor, S; Shen, ML, 2001
)
2.01
"Disulfiram has no effect on macromolecular synthesis of the host cells."( Effect of tetraethyl thiuram disulfide (disulfiram) on the multiplication of enveloped viruses.
Carić-Lazar, M; Rott, R; Scholtissek, C, 1975
)
1.24
"Disulfiram (200 mg/kg) has a prolonged inhibitory effect; this effect is enhanced and extended when the disulfiram is combined with acetaldehyde (400 mg/kg)."( Inhibition of the metabolism of ethyl carbamate by acetaldehyde.
Hurst, HE; Kemper, R; Kurata, N; Waddell, WJ,
)
0.85
"Disulfiram has no proven effect on the long-term outcome of alcoholism."( Disulfiram treatment of alcoholism.
Moore, RD; Wright, C, 1990
)
2.44
"That disulfiram has been shown to inhibit dopamine beta-hydroxylase in vitro suggests an etiologic role for dopaminergic pathways in at least some cases of Capgras syndrome."( Capgras delusion and seizures in association with therapeutic dosages of disulfiram.
Daniel, DG; Swallows, A; Wolff, F, 1987
)
0.96
"Disulfiram has long been used in the treatment of chronic alcoholism. "( Plasma extracellular superoxide dismutase and erythrocyte Cu,Zn-containing superoxide dismutase in alcoholics treated with disulfiram.
Marklund, SL; Ohman, M, 1986
)
1.92
"Disulfiram has been widely used as an adjunct in the treatment of alcoholism and has relatively few side effects. "( Disulfiram hepatotoxicity: case report.
Black, JL; Richardson, JW, 1985
)
3.15

Actions

Disulfirame is a rare cause of peripheral neuropathy in subjects with chronic alcoholism. Disulfiram can inhibit inflammation and fibrosis in renal fibrosis rats by inhibiting GSDMD.

ExcerptReferenceRelevance
"As disulfiram (DSF) can inhibit both P-gp and CSCs, we hypothesized that co-treatment of DTX and DSF could sensitize the drug-resistant breast cancer cells."( Overcoming drug resistance with a docetaxel and disulfiram loaded pH-sensitive nanoparticle.
Biswas, S; Kumbham, S; Maravajjala, KS; Paul, M; Roy, A; Swetha, KL, 2023
)
1.68
"Disulfiram can inhibit EMT of Smad4 mutant and Smad4 non-mutated OSCC cells by blocking ERK phosphorylation in the MAPK signaling pathway."( [Effect of disulfiram on epithelial-mesenchymal transformation of oral squamous cell carcinoma cells].
Jiang, Y; Wang, XM, 2020
)
2.39
"Disulfiram can inhibit inflammation and fibrosis in renal fibrosis rats by inhibiting GSDMD."( Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis.
Han, X; Zhang, R; Zhang, Y, 2021
)
3.51
"Disulfiram and metals inactivate key oncoproteins resulting in anti-neoplastic activity. "( A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
Agarwal, N; Akerley, WL; Boucher, KM; Brittain-Blankenship, M; Buys, SS; Grossman, KF; Kelley, KC; Kennedy, TP; Kosak, KM; McGregor, KA; Sborov, DW; Shami, PJ; Sharma, S; Terrazas, MC; Thorne, KM; Ward, JH; Weis, JR; Werner, TL, 2021
)
2.34
"Disulfiram toxicity can cause multiple neurologic problems, including a reversible distal sensorimotor axonal polyneuropathy. "( Neuromuscular ultrasound findings in polyneuropathy secondary to disulfiram.
Cartwright, MS; Magruder, JL; Panea, OR; Stone, SL; Vann, RC; Walker, FO, 2014
)
2.08
"Disulfiram can cause toxic optic neuropathy, which can recover after discontinuing the medication, even after a long period of intoxication."( [Reversible optic neuropathy related to disulfiram].
Milea, D; Trélohan, A, 2011
)
2.08
"Disulfiram therapy may allow (1) prolonged abstinence leading to successful antiviral therapy for HCV, and (2) time to begin behavioral treatments that facilitate long-term abstinence."( Hepatitis C in alcohol dependence:drinking versus disulfiram.
Beresford, TP; Kulig, CC, 2005
)
1.3
"Disulfiram may cause a peripheral neuropathy that is considered dose- and duration-of-exposure-related. "( Disulfiram neuropathy: two cases of distal axonopathy.
Broglio, L; Buzio, S; Choub, A; Cotelli, MS; Filosto, M; Lazzarini, C; Mancuso, M; Padovani, A; Pasolini, MP; Scarpelli, M; Tentorio, M, 2008
)
3.23
"Disulfiram did enhance some of the subjective effects of dextroamphetamine including ratings of "high," "anxious," "bad drug effects," "want more drug" and "drug liking" and was also associated with decreased performance in the SART test."( Disulfiram enhances subjective effects of dextroamphetamine in humans.
Hill, K; Kosten, T; Poling, J; Sewell, A; Sofuoglu, M; Waters, A, 2008
)
2.51
"Disulfiram can cause a fulminant polyneuropathy that is not always benign and reversible."( Fulminant polyneuritis after overdose of disulfiram and ethanol.
Johnson, PC; Merkley, R; Rothrock, JF; Rothrock, SM, 1984
)
1.25
"Disulfiram is known to produce toxic encephalopathy and peripheral neuropathy. "( [Polyneuropathy caused by disulfiram poisoning].
Busse, O; Schütz, HJ; Vuia, O, 1983
)
2.01
"Disulfiram did not inhibit this enzyme under the conditions used in this study, however p-hydroxymercuribenzoate rapidly inactivated the enzyme."( Human corneal aldehyde dehydrogenase: purification, kinetic characterisation and phenotypic variation.
Holmes, RS; King, G, 1993
)
1.01
"Disulfiram was used because it is metabolized to two molecules of dithiocarb and is hypothetically of value."( Acute nickel carbonyl poisoning.
Dean, BS; Krenzelok, EP; Kurta, DL, 1993
)
1.01
"Disulfirame is a rare cause of peripheral neuropathy in subjects with chronic alcoholism. "( [Peripheral neuropathies caused by disulfiram].
Bregigeon, M; Brosset, C; Dano, P; Tammam, D, 1996
)
2.01
"Disulfiram is known to cause hepatitis, which is sometimes fatal. "( Safety issues concerning the use of disulfiram in treating alcohol dependence.
Chick, J, 1999
)
2.02
"As disulfiram treatment may cause severe side effects it is recommended that the lowest possible dosage by employed."( [Disulfiram neuropathy].
Klugkist, H; Preuss, S, 1992
)
1.71
"Disulfiram will produce an aversive reaction with ethanol, usually at a dose between 250 mg/day and 500 mg/day, although some patients may not have an aversive reaction at this level. "( Disulfiram treatment of alcoholism.
Moore, RD; Wright, C, 1990
)
3.16

Treatment

Disulfiram (DSF) has shown some clinical effectiveness in treating addiction to cocaine, nicotine, and pathological gambling. Despite its limitations, it remains a viable option as a treatment for alcohol dependence and has shown recent promise in treating co-morbid alcohol dependence.

ExcerptReferenceRelevance
"Disulfiram treatment reduces PH progression through suppressing vascular remodelling by inhibiting GSDMD cleavage and pyroptosis. "( Disulfiram attenuates hypoxia-induced pulmonary hypertension by inhibiting GSDMD cleavage and pyroptosis in HPASMCs.
Hu, S; Li, F; Wang, L; Wang, T; Xu, Y, 2022
)
3.61
"Disulfiram treatment did not alter the expression of Na"( Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Hong, JH; Hwang, S; Shin, DM, 2019
)
1.5
"Disulfiram treatment also inhibited phosphorylating and proton leak-dependent respiration."( Protein S-glutathionylation lowers superoxide/hydrogen peroxide release from skeletal muscle mitochondria through modification of complex I and inhibition of pyruvate uptake.
Gardiner, D; Gill, RM; Mailloux, RJ; O'Brien, M; Young, A, 2018
)
1.2
"Disulfiram treatment for alcohol dependence is used with acceptable outcomes. "( Disulfiram--alcohol reaction mimicking an acute coronary syndrome.
Amuchastegui, M; Amuchastegui, T; Donohue, T, 2014
)
3.29
"Disulfiram is a viable treatment option for the high-risk population studied here. "( Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment.
Heilmann, M; Lieb, B; Scherbaum, N; Specka, M,
)
2.03
"Disulfiram (DSF), a treatment for alcohol use disorders, has shown some clinical effectiveness in treating addiction to cocaine, nicotine, and pathological gambling. "( N-acetyl-S-(N,N-diethylcarbamoyl) cysteine in rat nucleus accumbens, medial prefrontal cortex, and in rat and human plasma after disulfiram administration.
Caspers, MJ; Faiman, MD; Heemskerk, AA; Kaul, S; Lunte, CE; McCance-Katz, EF; Prisinzano, TE; Williams, TD; Winefield, RD, 2015
)
2.06
"Disulfiram treatment, despite its limitations, remains a viable option as a treatment for alcohol dependence and has shown recent promise in treating (1) those with co-morbid alcohol dependence and post-traumatic stress disorder, (2) those with co-morbid cocaine- and alcohol-dependence, and (3) those with cocaine-dependence alone. "( Disulfiram: an old therapeutic with new applications.
Barth, KS; Malcolm, RJ, 2010
)
3.25
"Disulfiram efficacy in treatment of cocaine addiction is attributed to the inhibition of dopamine-β-hydroxylase and reduction in brain noradrenaline (NA)/dopamine (DA) ratio."( Disulfiram stimulates dopamine release from noradrenergic terminals and potentiates cocaine-induced dopamine release in the prefrontal cortex.
Cadeddu, R; Devoto, P; Flore, G; Gessa, GL; Saba, P, 2012
)
3.26
"Disulfiram or nepicastat treatment had no effect on behavioral responses to cocaine in Dbh -/- mice."( Chronic inhibition of dopamine β-hydroxylase facilitates behavioral responses to cocaine in mice.
Gaval-Cruz, M; Iuvone, PM; Liles, LC; Weinshenker, D, 2012
)
1.1
"Disulfiram treatment was associated with decreases in days hospitalized but not with changes in work status."( Disulfiram treatment for alcoholism in severe mental illness.
Fox, L; Mueser, KT; Noordsy, DL; Wolfe, R,
)
2.3
"Disulfiram treatments also decreased cocaine clearance for the 0.5 mg/kg cocaine dose (p=0.002 and<0.001)."( Disulfiram effects on responses to intravenous cocaine administration.
Baker, JR; Jatlow, P; McCance-Katz, EF, 2007
)
2.5
"The disulfiram treatment induced elevated (P less than 0.001) levels of 5-hydroxytryptophol."( Concentration of serotonin metabolites in the cerebrospinal fluid from alcoholics before and during disulfiram therapy.
Beck, O; Borg, S; Holmstedt, B; Kvande, H; Shröder, R, 1980
)
0.96
"Disulfiram treatment of alcoholism has been difficult to evaluate in controlled studies because the study design must contend with problems unique to this drug. "( Veterans Administration cooperative study of disulfiram in the treatment of alcoholism: study design and methodological considerations.
Derman, R; Fuller, RK; Lee, KK; Williford, WO, 1984
)
1.97
"The Disulfiram Assurance treatment resulted in almost total sobriety for married or (cohabitating) clients but had little benefit for the single ones."( Alcoholism treatment by disulfiram and community reinforcement therapy.
Azrin, NH; Godley, M; Meyers, R; Sisson, RW, 1982
)
1.05
"Only disulfiram treatment elicited an increase in PHM activity extracted from cardiac atrium."( Peptide alpha-amidation: differential regulation by disulfiram and its metabolite, diethyldithiocarbamate.
Altarac, M; Mueller, GP, 1995
)
1
"Disulfiram treatment significantly diminished this increase."( Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation.
Armstrong, AS; Artru, A; Cox, K; Gunn, K; Karol, MD; Kharasch, ED, 1995
)
1.01
"Disulfiram treatment completely abolished the rise in plasma fluoride concentration."( Clinical enflurane metabolism by cytochrome P450 2E1.
Bosse, S; Kharasch, ED; Mautz, D; Thummel, KE, 1994
)
1.01
"Disulfiram treatment decreased both peaks depending on disulfiram dose and length of treatment, with peak I being more sensitive to inactivation than peak II."( In vivo effects of disulfiram and cyanamide on canine liver aldehyde dehydrogenase isoenzymes as detected by high-performance (pressure) liquid chromatography.
Rymas, K; Sanny, CG, 1993
)
1.34
"Disulfiram pretreatment markedly decreased chlorzoxazone elimination clearance to 15% of control values (from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p < 0.005), prolonged the elimination half-life (from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p < 0.001), and caused a twofold increase in peak plasma chlorzoxazone concentrations (20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p < 0.001)."( Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.
Kharasch, ED; Lillibridge, JH; Mhyre, J; Thummel, KE, 1993
)
1.39
"Disulfiram 250 mg/day treatment significantly increased plasma cocaine concentrations (p = .013), heart rate (cocaine 1 mg/kg, p = .046), and systolic (cocaine 2 mg/kg p = .003) and diastolic (cocaine 2 mg/kg, p = .022) blood pressure. "( Chronic disulfiram treatment effects on intranasal cocaine administration: initial results.
Jatlow, P; Kosten, TR; McCance-Katz, EF, 1998
)
2.18
"Disulfiram treatment was associated with significantly better retention in treatment, as well as longer duration of abstinence from alcohol and cocaine use. "( Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram.
Ball, SA; Carroll, KM; McCance, E; Nich, C; Rounsavile, BJ, 1998
)
1.98
"Disulfiram treatment increased plasma cocaine concentrations three to six times and significantly increased cocaine-associated cardiovascular responses, but did not significantly alter behavioral responses to cocaine."( Disulfiram effects on acute cocaine administration.
Jatlow, P; Kosten, TR; McCance-Katz, EF, 1998
)
2.46
"Disulfiram treatment decreased 6-hydroxychlorzoxazone formation clearance by nearly 95% but effected only a modest decrease in vesnarinone apparent oral clearance (5.7 +/- 1.0 vs."( Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
Bramer, SL; Cowart, TD; Frye, RF; Tammara, B, 1999
)
1.43
"Disulfiram treated subjects decreased the quantity and frequency of cocaine use significantly more than those treated with placebo. "( Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts.
Carroll, KM; Frankforter, T; Gordon, LT; McCance-Katz, EF; Nich, C; Petrakis, IL; Rounsaville, BJ, 2000
)
3.19
"In disulfiram-treated rats with a low DBH-activity, a fall in blood pressure was observed at acetaldehyde levels being slightly higher than those found in control rats."( Blood pressure response to ethanol in relation to acetaldehyde levels and dopamine-beta-hydroxylase activity in rats pretreated with disulfiram, cyanamide and coprine.
Hellström, E; Tottmar, O, 1979
)
0.98
"Disulfiram treatment reduced the acute lethal and hepatotoxic effects of inhaled VDC and reduced the levels of covalent bound radioactivity in the liver and kidney after the intraperitoneal administration of 14C-VDC."( Effect of various treatments on toxicity of inhaled vinylidene chloride.
Lee, CC; Minor, JL; Seifter, J; Short, RD; Winston, JM, 1977
)
0.98
"Disulfiram treatment caused marked elevations of circulating blood acetone levels in rat and man. "( Disulfiram-induced acetonemia in the rat and man.
DeMaster, EG; Nagasawa, HT, 1977
)
3.14
"As disulfiram treatment may cause severe side effects it is recommended that the lowest possible dosage by employed."( [Disulfiram neuropathy].
Klugkist, H; Preuss, S, 1992
)
1.71
"In disulfiram-treated rats, only 35 to 36% of the administered 14C was eliminated in the urine with 41 to 55% as unchanged EDC in the breath."( Ethylene dichloride: the influence of disulfiram or ethanol on oncogenicity, metabolism, and DNA covalent binding in rats.
Cheever, KL; Cholakis, JM; el-Hawari, AM; Kovatch, RM; Weisburger, EK, 1990
)
1.06
"Disulfiram and cyanamide treatment produced an approximately 2-fold increase in 5-hydroxytryptophol and a slight reduction in 5-hydroxyindole-acetic acid."( 5-Hydroxyindoleacetic acid and 5-hydroxytryptophol levels in rat brain: effects of ethanol, pyrazole, cyanamide and disulfiram treatment.
Beck, O; Eriksson, CJ; Kiianmaa, K; Lundman, A, 1986
)
1.2
"With disulfiram pretreatment, the plasma clearance of theophylline was decreased from 105.7 +/- 10.2 (mean +/- SEM) to 83.1 +/- 8.1 ml/kg per hour (p less than 0.001) in the 250 mg group and from 94.3 +/- 13.3 to 65.4 +/- 10.7 ml/mg per hour (p less than 0.001) in the 500 mg group."( Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics.
Bush, ED; Costello, P; Day, JD; Dewey, LV; Jue, SG; Loi, CM; Vestal, RE, 1989
)
0.98
"Disulfiram pretreatment reduced 24 hour urinary excretion of acetaminophen-mercapturate and- cysteine while excretion of -sulfate and -glucuronide was unchanged."( Disulfiram prevents acetaminophen hepatotoxicity in rats.
Jørgensen, L; Poulsen, HE; Thomsen, P, 1988
)
2.44
"Pretreatment with disulfiram (5.6 mg/kg) produced a significant downward shift in the d-methamphetamine dose-response function; surprisingly, lower and higher pretreatment doses (3.0 mg/kg; 10 mg/kg) were ineffective."( Limited modulation of the abuse-related behavioral effects of d-methamphetamine by disulfiram.
Bergman, J; de Moura, FB; Kohut, SJ, 2018
)
1.03
"Pretreatment of disulfiram in MD model mice increased the copper level in the brain (0.59 ± 0.28 %ID/g) at 24 h compared with MD model mice without disulfiram (0.07 ± 0.05 %ID/g) (P < 0.05)."( Disulfiram enhanced delivery of orally administered copper into the central nervous system in Menkes disease mouse model.
Hamazaki, T; Hoshina, T; Kodama, H; Kudo, S; Nakatani, Y; Nozaki, S; Shintaku, H; Watanabe, Y, 2018
)
2.26
"Treatment with disulfiram was associated on day 7 with resolution of metabolic acidosis and slowing of the decrease in acetonitrile concentration."( Disulfiram inhibition of cyanide formation after acetonitrile poisoning.
Benoit, D; Boussery, K; Buylaert, W; Colin, P; De Paepe, P; De Smet, J; Decavele, AS; Depuydt, P; Stove, C; Van Bocxlaer, J; Verstraete, A, 2016
)
2.22
"One treatment with disulfiram (200 mg/kg) lasted 4 but not 6 days."( Hypotensive response of ethanol in rats pretreated with disulfiram or nitrefazole.
Bloom, FE; Koda, LY; Madamba, SG, 1984
)
0.83
"Treatment with disulfiram (DSF, 1000 mg/kg p.o.) 2 or 6 h prior to s.c. "( Influence of pretreatment with disulfiram (DSF) on the acute toxicity of cyclophosphamide (CP) in male Sprague-Dawley rats.
Habs, H; Habs, M; Schmähl, D, 1981
)
0.9
"Pretreatment with disulfiram (DSF, 1000 mg/kg p.o.) 2 h prior to intraperitoneal injection of 1-(2-hydroxyethyl)3-(2-chloroethyl)-3-nitrosourea (HECNU, NSC 29485) reduced the acute toxicity of HECNU by 50% in Sprague--Dawley rats. "( Effect of the pretreatment with disulfiram on the toxicity and antitumor activity of 1-(2-hydroxyethyl)-3-(2-chloroethyl)-3-nitrosourea in Sprague--Dawley rats.
Habs, H; Habs, M, 1981
)
0.88
"Treatment with disulfiram, an inhibitor of the peptidylglycine alpha-amidating monooxygenase (PAM), reduced levels of TRH in the PP by 20%."( Regulation of thyrotropin-releasing hormone in the posterior pituitary.
de Greef, WJ; Klootwijk, W; Linkels, E; Rondeel, JM; van Haasteren, GA; Visser, TJ, 1995
)
0.63
"Pretreatment with disulfiram, an inhibitor of liver aldehyde dehydrogenase, potentiated the emetogenic effects of ethanol."( Ethanol-induced emesis in the house musk shrew, Suncus murinus.
Chen, Y; Matsuki, N; Saito, H, 1997
)
0.62
"Pretreatment with disulfiram or CS2 causes a complete, although transient, inhibition of exhaled 14CO2, decreases urinary MAM, and increases significantly the levels of unmetabolized AOM in the exhaled air and in urine."( Investigations into the metabolism and mode of action of the colon carcinogens 1,2-dimethylhydrazine and azoxymethane.
Fiala, ES, 1977
)
0.58
"Pretreatment with disulfiram prevented infusions of angiotensin II from increasing the responses to spinal sympathetic outflow stimulation."( Sympathetic component of the pressor response to angiotensin II in the pithed rat after pretreatment with disulfiram.
Day, MD; Hall, JM, 1975
)
0.79
"The treatment with disulfiram is useful but incomplete."( [A catamnestic study of recovered alcoholics].
Bendia, MT; Giaquinto, S; Massi, G; Ricolfi, A; Vitali, S, 1979
)
0.58
"2. Treatment with disulfiram causes enhanced elimination of azomethane in the expired air, inhibition of CO2 production, and decreased levels of 1,2-dimethylhydrazine metabolites in the urine."( Inhibition of 1,2-dimethylhydrazine metabolism by disulfiram.
Bobotas, G; Fiala, ES; Kulakis, C; Weisburger, JH,
)
0.71
"Pretreatment with disulfiram (DSF, 500 mg/kg), a known inhibitor of DMH metabolism, totally prevented intestinal and Zymbal gland tumors in Wistar rats."( Effect of metabolic inhibitors, methylxanthines, antioxidants, alkali metals, and corn oil on 1,2-dimethylhydrazine carcinogenicity in rats.
Balansky, R; Blagoeva, P; de Flora, S; Mircheva, Z; Pozharisski, K,
)
0.45

Toxicity

The combination of prolonged high-dose disulfiram and vorinostat was not safe in PWH on ART and should not be pursued despite evidence of latency reversal. The toxic effect was not due to an inhibition of superoxide dismutase.

ExcerptReferenceRelevance
" If this is so, then some other toxic effects of carbon disulfide, including parkinsonism, choreoathetosis, and thalamic syndrome may follow the ingestion of more than 5 g of disulfiram by adults, and individuals receiving as little as 125 mg of disulfiram per day may be at a three- to four-fold greater risk for arteriosclerotic cardiovascular disease than a comparable population not receiving the drug."( Disulfiram toxicity and carbon disulfide poisoning.
Rainey, JM, 1977
)
1.89
" The toxic effect was not due to an inhibition of superoxide dismutase, nor did disulfiram significantly affect the level of glutathione or change the reduced to oxidized glutathione ratio in the lung."( Enhancement by disulfiram (Antabuse) of toxic effects of 95 to 97% O2 on the rat lung.
Bernstein, SP; Deneke, SM; Fanburg, BL, 1979
)
0.84
" Early studies by several investigators demonstrated that similar compounds such as alpha, beta-unsaturated aldehyde-cysteine adducts have toxic (carcinostatic) activity against Ehrlich ascites tumor cells implanted in mice."( Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat.
Horvath, JJ; Witmer, CM; Witz, G, 1992
)
0.28
" Thus, neither DSF nor DDTC impaired the antitumour effect of IFX and both diminished its adverse effects."( Drug interaction effects on antitumour drugs (VIII): prevention of ifosfamide-induced urotoxicity by disulfiram and its effect on antitumour activity and acute toxicity of alkylating agents in mice.
Ishikawa, M; Sasaki, K; Takayanagi, Y, 1991
)
0.5
" The action of disulfiram as an inhibitor of dopamine beta hydroxylase provides a possible mechanism for the cerebral toxic effect, but nonetheless the various interpretations remain largely speculative."( 'Catatonia' due to disulfiram toxicity.
Fisher, CM, 1989
)
0.96
" The toxicity was prevented by inhibitors of alcohol dehydrogenase and augmented by the aldehyde dehydrogenase inhibitor disulfiram, suggesting that the toxic metabolite was the reactive aldehyde acrolein."( Mechanism of allyl alcohol toxicity and protective effects of low-molecular-weight thiols studied with isolated rat hepatocytes.
Ohno, Y; Ormstad, K; Orrenius, S; Ross, D, 1985
)
0.48
" These results indicate that acrolein is the toxic metabolite responsible for the renal cell injury following exposure to allyl alcohol, and unless immediately inactivated acrolein interacts with critical nucleophilic sites of the cell and initiates cell injury."( Allyl alcohol toxicity in isolated renal epithelial cells: protective effects of low molecular weight thiols.
Jones, TW; Ohno, Y; Ormstad, K, 1985
)
0.27
" Oral disulfiram protects rats from toxic effects at some circadian stages but not others."( Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences.
Berestka, J; Hrushesky, WJ; Lakatua, D; Langevin, T; Olshefski, R; Reusch, JE; Reusch, JJ; Roemeling, RV; Wick, MR, 1986
)
1.05
" Low doses (less than 800 mg/kg) produced minimal toxic effects within an initial 4-h observation period."( Toxicity of benzyl alcohol in adult and neonatal mice.
George, WJ; Gershanik, JJ; Lertora, JJ; McCloskey, SE; White, L, 1986
)
0.27
" It appears from these studies that the acute toxic effect of CYT on the granulocyte/macrophage progenitor cells is not enhanced by DSF."( The effect of disulfiram on cyclophosphamide-mediated myeloid toxicity.
Ershler, WB; Foster, RS; Gamelli, RL; Hacker, MP, 1986
)
0.63
" The intraperitoneal LD50 of lobeline sulfate following SKF 525-A (75 mg/kg), phenobarbital (PB), and 3-methylcholanthrene (3-MC) were 18."( Effects of SKF 525-A, phenobarbital and 3-methylcholanthrene on the toxicity of lobeline sulfate.
Kim, HL, 1985
)
0.27
" Thus, this study shows that agents which sensitize or protect rats from the toxic effects of ANIT, correspondingly stimulate or inhibit the oxidative desulfuration of [35S]ANIT in vivo."( Effect of thiocarbonyl compounds on alpha-naphthylisothiocyanate-induced hepatotoxicity and the urinary excretion of [35S]alpha-naphthylisothiocyanate in the rat.
Hanzlik, RP; Traiger, GJ; Vyas, KP, 1984
)
0.27
" When animals were pretreated with inhibitors of alcohol metabolism followed by a testicular toxic dose of EGME (500 mg/kg), an inhibitor of alcohol dehydrogenase (pyrazole) offered complete protection."( Testicular toxicity produced by ethylene glycol monomethyl and monoethyl ethers in the rat.
Creasy, DM; Foster, JR; Foster, PM; Gray, TJ, 1984
)
0.27
" The acute LD50 was reduced from 236 mg/kg after application of CP alone to 90 mg/kg and 95 mg/kg after pretreatment with DSF 2 and 6 h prior to CP administration, respectively."( Influence of pretreatment with disulfiram (DSF) on the acute toxicity of cyclophosphamide (CP) in male Sprague-Dawley rats.
Habs, H; Habs, M; Schmähl, D, 1981
)
0.55
" Pretreatment with DSF (1000 mg/kg) resulted in identical or slightly higher life expectancies; it thus reduced the toxic side effects of HECNU without inhibiting its antitumor potency."( Effect of the pretreatment with disulfiram on the toxicity and antitumor activity of 1-(2-hydroxyethyl)-3-(2-chloroethyl)-3-nitrosourea in Sprague--Dawley rats.
Habs, H; Habs, M, 1981
)
0.55
" DDTC and disulfiram themselves produced olfactory mucosal lesions in the rat, whereas DDTC protected against the olfactory toxic effects of dichlobenil in the mouse."( Olfactory toxicity of diethyldithiocarbamate (DDTC) and disulfiram and the protective effect of DDTC against the olfactory toxicity of dichlobenil.
Deamer, NJ; Genter, MB, 1995
)
0.94
" The folate-reduced (FR) rat is an excellent animal model that mimics characteristic human methanol toxic responses."( Role of retinal metabolism in methanol-induced retinal toxicity.
Garner, CD; Lee, EW; Louis-Ferdinand, RT; Terzo, TS, 1995
)
0.29
" These results suggest that dibromoalkane-induced cell lysis is due to lipid peroxidation as well as cytochrome P450-dependent formation of toxic bromoaldehydic metabolites which can bind with cellular macromolecules."( Molecular mechanisms of dibromoalkane cytotoxicity in isolated rat hepatocytes.
Khan, S; O'Brien, PJ; Sood, C, 1993
)
0.29
" Of all tested reagents, organic mercury compounds arose as the most toxic reagents."( Hepatotoxic effects of SH-reagents in human and rat hepatocyte cultures and in situ perfused rat livers.
Boot, JH, 1996
)
0.29
" Of the less serious adverse effects, tiredness, headache and sleepiness are the most common."( Safety issues concerning the use of disulfiram in treating alcohol dependence.
Chick, J, 1999
)
0.58
"It has previously been shown that rats pre-treated with butylated hydroxyanisole (BHA), a well-known inducer of the enzyme DT-diaphorase, are protected against the toxic effects of 2-methyl-1,4-naphthoquinone but are made more susceptible to the harmful action of 2-hydroxy-1,4-naphthoquinone."( Effect of inducers of DT-diaphorase on the toxicity of 2-methyl- and 2-hydroxy-1,4-naphthoquinone to rats.
Munday, CM; Munday, R; Smith, BL, 1999
)
0.3
" Disulfiram appeared to be safe when added to intermittent, directly observed isoniazid-containing tuberculosis treatment, and was useful in managing complications of alcohol abuse."( Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis.
Breese, P; Burman, WJ; Cohn, D; Reves, R; Terra, M, 2002
)
1.48
" The primary constituent, R-(+)-pulegone, is metabolized via hepatic cytochrome P450 to toxic intermediates."( Mitigation of pennyroyal oil hepatotoxicity in the mouse.
Bond, GR; Goetz, RJ; Lindsell, CJ; Otten, EJ; Sztajnkrycer, MD, 2003
)
0.32
" So, these results suggest that an early production of DOPAL could produce delayed toxic effects on SH-SY5Y cells."( Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.
Bonnet, JJ; Costentin, J; Dingeval, MG; Janin, F; Legros, H, 2004
)
0.58
" It is not possible to generalize with regard to the effects of modulation of tissue levels of DT-diaphorase on naphthoquinone toxicity in vivo, since this may change not only the severity of the toxic effects, but also the target organ specificity."( Effect of inducers of DT-diaphorase on the haemolytic activity and nephrotoxicity of 2-amino-1,4-naphthoquinone in rats.
Munday, CM; Munday, R; Smith, BL, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"We previously determined that the dithiocarbamate pesticide sodium metam (NaM) and its active ingredient methylisothiocyanate (MITC) were developmentally toxic causing notochord distortions in the zebrafish."( Dithiocarbamates have a common toxic effect on zebrafish body axis formation.
Alzarban, N; La Du, JK; Tanguay, RL; Tilton, F; Vue, M, 2006
)
0.33
" When patients are screened for medical and psychiatric stability, and are evaluated for drug interactions, disulfiram has an acceptable side-effect profile for the treatment of cocaine dependence with or without alcohol dependence."( The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice.
Lechner, W; Malcolm, R; Olive, MF, 2008
)
0.92
"1 to 180 mg/kg and reduced the production of a potential toxic metabolite chloroacetaldehyde (CAA) in animal plasma."( Protective effects of fomepizole on 2-chloroethanol toxicity.
Chen, YT; Hung, DZ; Liao, JW, 2010
)
0.36
"Disulfiram has been shown to be efficacious and safe in the treatment of alcohol relapse prevention."( Urinary ethylglucuronide assessment in patients treated with disulfiram: a tool to improve verification of abstention and safety.
Grosshans, M; Hermann, D; Kiefer, F; Koopmann, A; Mann, K; Mutschler, J,
)
1.82
" In contrast, ethanol produced adverse ECG changes including QTc prolongation and a DER consisting of hypotension, tachycardia, nausea, and flushing in disulfiram-treated subjects."( A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.
Anderson, A; De La Garza, R; Elkashef, A; Kahn, R; Mojsiak, J; Murff, WL; Newton, TF; Rivera, O; Roache, JD; Wallace, CL, 2011
)
0.77
" However, the optimal therapeutic aftercare regimen for patients is still unclear, and disulfiram is associated with numerous adverse events."( Safety and efficacy of long-term disulfiram aftercare.
Dirican, G; Grosshans, M; Gutzeit, A; Mutschler, J,
)
0.64
" No serious adverse events were recorded."( Safety and efficacy of long-term disulfiram aftercare.
Dirican, G; Grosshans, M; Gutzeit, A; Mutschler, J,
)
0.41
"Although case observations should be interpreted with caution, the present results suggest that disulfiram is safe and efficient in supervised long-term treatment of alcohol-dependent patients."( Safety and efficacy of long-term disulfiram aftercare.
Dirican, G; Grosshans, M; Gutzeit, A; Mutschler, J,
)
0.63
" A toxic product of lipid peroxidation, (±)-4-hydroxy-2E-nonenal (HNE) leads to membrane disruption and formation of HNE-protein adducts and such adducts have been detected in PD brain tissues."( Modulation of aldehyde dehydrogenase activity affects (±)-4-hydroxy-2E-nonenal (HNE) toxicity and HNE-protein adduct levels in PC12 cells.
Kong, D; Kotraiah, V, 2012
)
0.38
" These results indicate that acetaldehyde is generated as a by-product during steroidogenesis and can exert toxic effects to impair the differentiation of granulosa cells, reduce ovulation and decrease oocyte quality."( Endogenous acetaldehyde toxicity during antral follicular development in the mouse ovary.
Fujita, Y; Ikeda, C; Kawai, T; Kawashima, I; Mihara, T; Negishi, H; Richards, JS; Shimada, M, 2012
)
0.38
"Disulfiram was safe and well tolerated."( A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.
Andrade, A; Bacchetti, P; Buckheit, R; Bumpus, NN; Chander, G; Deeks, SG; Eisele, E; Emad, F; Hoh, R; Kennedy, M; Lai, J; McCance-Katz, EF; Siliciano, JD; Siliciano, RF; Spivak, AM, 2014
)
2.08
"MVA-B was safe and well tolerated."( Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Alcamí, J; Alvarez-Fernández, C; Arnaiz, JA; Benito, JM; Blanco, J; Brander, C; Carrillo, J; Climent, N; Clotet, B; Esteban, M; García, F; García-Arriaza, J; Gatell, JM; Gómez, CE; Gonzalez, N; Guardo, AC; Jiménez, JL; León, A; López Bernaldo de Quirós, JC; Martinez-Picado, J; Mothe, B; Muñoz-Fernández, MÁ; Peña, J; Perdiguero, B; Pich, J; Plana, M; Puertas, MC; Rallón, N; Rosàs, M; Sánchez-Palomino, S, 2015
)
0.42
"MVA-B vaccination was a safe strategy to increase Gag-specific T cell responses in chronically HIV-1-infected individuals, but it did not have a major impact on the latent reservoir or the rebound of plasma viral load after interruption of cART when given alone or in combination with disulfiram."( Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Alcamí, J; Alvarez-Fernández, C; Arnaiz, JA; Benito, JM; Blanco, J; Brander, C; Carrillo, J; Climent, N; Clotet, B; Esteban, M; García, F; García-Arriaza, J; Gatell, JM; Gómez, CE; Gonzalez, N; Guardo, AC; Jiménez, JL; León, A; López Bernaldo de Quirós, JC; Martinez-Picado, J; Mothe, B; Muñoz-Fernández, MÁ; Peña, J; Perdiguero, B; Pich, J; Plana, M; Puertas, MC; Rallón, N; Rosàs, M; Sánchez-Palomino, S, 2015
)
0.59
" Therefore, new therapeutic approaches are urgently needed for MDS patients harboring adverse prognostic factors."( Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy.
Bi, S; Chen, K; Deng, M; Feng, L; Guo, C; He, J; Jiang, Y; Li, Z; Pu, X; Shi, P; Song, H; Xu, B; Zha, J; Zhao, H, 2021
)
2.06
"The combination of prolonged high-dose disulfiram and vorinostat was not safe in PWH on ART and should not be pursued despite evidence of latency reversal."( Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
Blennow, K; Bumpus, N; Burger, D; Chang, J; Dantanarayana, A; Evans, VA; Fisher, K; Gisslen, M; Hagenauer, M; Heck, CJS; Howell, BJ; Lau, JSY; Lee, S; Lewin, SR; McMahon, JH; Palmer, S; Rasmussen, TA; Solomon, A; Symons, J; Tennakoon, S; Wu, G; Zerbato, JM; Zetterberg, HH; Zuck, P, 2022
)
1.28

Pharmacokinetics

The development of disulfiram-like effects is closely related to the pharmacokinetic profile of NMTT released from its parent drugs. Tricyclic pharmacokinetics parameters, determined from plasma samples over 48 hours, indicated decreased total body clearance, increased elimination half-life, and higher peak plasma levels.

ExcerptReferenceRelevance
" Pharmacokinetic parameters and enzyme kinetic data both in normal and in tumor-bearing animals will be presented."( Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect.
Bartosek, I; Colombo, T; Donelli, MG; Guaitani, A; Martini, A; Modica, R; Pacciarini, MA, 1976
)
0.26
" A pharmacokinetic model featuring the liver compartment for acetaldehyde was used to estimate pharmacokinetic parameters on the assumption that the distribution volumes of the central compartments were same for alcohol and acetaldehyde, and that the elimination rate of acetaldehyde from liver was large enough to isolate the liver compartment from the central compartment."( Effects of diethyldithiocarbamate, a metabolite of disulfiram, on the pharmacokinetics of alcohol and acetaldehyde in the rat.
Enomoto, K; Inahara, S; Maeda, K; Nishigaki, R; Umemura, K; Utsugi, K, 1985
)
0.52
" These results indicate that the development of disulfiram-like effects of NMTT-containing antibiotics is closely related to the pharmacokinetic profile of NMTT released from its parent drugs."( Pharmacokinetics of latamoxef and N-methyltetrazolethiol in rats associated with the development of disulfiram-like effects.
Matsubara, T; Ogawa, A; Oka, T; Otsubo, S, 1987
)
0.74
" In general, a two-compartment, steady-state pharmacokinetic model described the uptake data."( Inhalation pharmacokinetics of 1,2-dichloroethane after different dietary pretreatments of male Sprague-Dawley rats.
Igwe, OJ; Que Hee, SS; Wagner, WD, 1986
)
0.27
" Tricyclic pharmacokinetic parameters, determined from plasma samples over 48 hours, indicated decreased total body clearance, increased elimination half-life, and higher peak plasma levels during disulfiram treatment."( Pharmacokinetic interaction of disulfiram and antidepressants.
Barnhill, J; Boxenbaum, H; Ciraulo, DA, 1985
)
0.74
" Studies were conducted in male Sprague-Dawley rats and also in vitro using both rat liver mitochondrial and purified bovine mitochondrial low Km ALDH to investigate further the pharmacodynamic and pharmacokinetic characteristics of DETC-MeSO."( In vivo pharmacodynamic studies of the disulfiram metabolite S-methyl N,N-diethylthiolcarbamate sulfoxide: inhibition of liver aldehyde dehydrogenase.
Faiman, MD; Hart, BW, 1994
)
0.56
" The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion."( Clinical pharmacokinetics of acamprosate.
Chabac, S; Durbin, P; Houin, G; Hulot, T; Potgieter, A; Saivin, S, 1998
)
0.3
"Concomitant administration of diclofenac reduced the partial clearance of quinidine by N-oxidation by 27%, while no effect was found for other pharmacokinetic parameters of quinidine."( Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
Brosen, K; Damkier, P; Hansen, LL, 1999
)
0.62
" Nanotechnology based interventions have gained remarkable recognition in improving pharmacokinetic and pharmacodynamic profile of DSF by improving its stability and avoiding its degradation."( Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.
Ahmad, MM; Ahsan, A; Ahsan, HM; Aquib, M; Baig, MMFA; Farooq, MA; Hussain, Z; Jiajie, J; Khan, DH; Wande, DP; Wang, B, 2019
)
0.79
"The aim of the present review is to critically analyse all recent developments in designing various nanotechnology-based delivery systems, to ponder their relevance in improving stability, pharmacokinetic and pharmacodynamic profile, and achieving target-specific delivery of this agent to cancer cells to effectively eradicate cancer and abolish its metastasis."( Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.
Ahmad, MM; Ahsan, A; Ahsan, HM; Aquib, M; Baig, MMFA; Farooq, MA; Hussain, Z; Jiajie, J; Khan, DH; Wande, DP; Wang, B, 2019
)
0.79
" While the pharmacokinetics of ethanol metabolism through alcohol dehydrogenase have been thoroughly explored in previous studies, in this paper, we combined a base physiologically-based pharmacokinetic (PBPK) model with a whole-body genome-scale model (WBM) to gain further insight into the effect of other less explored processes and genetic variations on ethanol metabolism."( Integration of a physiologically-based pharmacokinetic model with a whole-body, organ-resolved genome-scale model for characterization of ethanol and acetaldehyde metabolism.
Mahadevan, R; Pei, W; Thiele, I; Zhu, L, 2021
)
0.62

Compound-Compound Interactions

Disulfiram alone or in combination with ethanol was administered orally for six weeks. MVA-B vaccination was a safe strategy to increase Gag-specific T cell responses in chronically HIV-1-infected individuals, but it did not have a major impact on the latent reservoir.

ExcerptReferenceRelevance
"Alcohol appears to interact with many drugs in many different and complicated ways."( [Alcohol and drug interactions].
Mombelli, G, 1978
)
0.26
" In the present study, we examined the effects of disulfiram (DSF) in combination with ifosfamide (IFX)."( Drug interaction effects on antitumour drugs (VIII): prevention of ifosfamide-induced urotoxicity by disulfiram and its effect on antitumour activity and acute toxicity of alkylating agents in mice.
Ishikawa, M; Sasaki, K; Takayanagi, Y, 1991
)
0.75
"In an experiment on Wistar male rats the authors studied the effects of teturam, diethyldithiocarbamate and Esperale in combination with L-DOPA on the consumption of alcohol and metabolism of biogenic amines in the brain."( [Increased efficacy of teturam combined with L-DOPA in experimental alcoholism in the rat].
Bobkova, NV; Gromova, EA; Khesin, II; Plakkhinas, LA; Tokareva, AE, 1986
)
0.27
"Pharmacokinetic drug-drug interactions which involve currently available benzodiazepines may be classified into two major categories: interactions which affect benzodiazepine rate of absorption, and interactions which affect clearance and, therefore, elimination half-life."( Benzodiazepine drug-drug interactions commonly occurring in clinical practice.
Abernethy, DR; Greenblatt, DJ; Ochs, HR; Shader, RI, 1984
)
0.27
"Pharmacokinetic drug-drug interactions which involve currently available benzodiazepines may be classified into 2 major categories: interactions which affect benzodiazepine rate of absorption, and interactions which affect clearance and, therefore, elimination 1/2-life."( Benzodiazepine drug-drug interactions commonly occurring in clinical practice.
Abernethy, DR; Greenblatt, DJ; Ochs, HR; Shader, RI, 1984
)
0.27
" The effect of disulfiram was augmented by combination with tryptophan plus lithium, although neither tryptophan or lithium prolonged the latency to clonic seizure."( Effect of disulfiram in combination with L-tryptophan and lithium on pentylenetetrazol-induced seizure.
Fukumori, R; Kitagawa, H; Minegishi, A; Satoh, T, 1982
)
1.02
"Disulfiram alone or in combination with ethanol was administered orally for six weeks."( The effect of prolonged administration of disulfiram alone or in combination with ethanol on some indices of lipid metabolism in the blood serum and hepatic tissue of the rat.
Janik, A; Mach, T,
)
1.84
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"There have been several reports of disulfiram intoxication, but little evidence of neurologic conditions resulting from disulfiram-induced brain damage combined with Wernicke encephalopathy-associated lesions."( A case of Wernicke encephalopathy combined with disulfiram intoxication.
Casoni, F; Costa, A; D'Errico, I; Fanucchi, S; Farina, LM; Micieli, G; Sinforiani, E; Tartara, E, 2013
)
0.92
"MVA-B vaccination was a safe strategy to increase Gag-specific T cell responses in chronically HIV-1-infected individuals, but it did not have a major impact on the latent reservoir or the rebound of plasma viral load after interruption of cART when given alone or in combination with disulfiram."( Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Alcamí, J; Alvarez-Fernández, C; Arnaiz, JA; Benito, JM; Blanco, J; Brander, C; Carrillo, J; Climent, N; Clotet, B; Esteban, M; García, F; García-Arriaza, J; Gatell, JM; Gómez, CE; Gonzalez, N; Guardo, AC; Jiménez, JL; León, A; López Bernaldo de Quirós, JC; Martinez-Picado, J; Mothe, B; Muñoz-Fernández, MÁ; Peña, J; Perdiguero, B; Pich, J; Plana, M; Puertas, MC; Rallón, N; Rosàs, M; Sánchez-Palomino, S, 2015
)
0.59
" We showed that protein kinase C agonists in combination with bromodomain inhibitor JQ1 or histone deacetylase inhibitors robustly induce HIV-1 transcription and virus production when directly compared with maximum reactivation by T cell activation."( Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
Bullen, CK; Durand, CM; Hill, AL; Laird, GM; Martin, AR; Rosenbloom, DI; Siliciano, JD; Siliciano, RF, 2015
)
0.42
" This phase I study aims to evaluate its safety, maximum tolerated dose (MTD), pharmacodynamic effect, and preliminary efficacy when combined with adjuvant temozolomide in GBM patients after standard chemoradiotherapy."( A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016
)
0.73
"Various cytotoxic agents were evaluated in combination with (131) I-MIP-1095 for their capacity to delay the growth of LNCaP cells cultured as multicellular tumour spheroids."( Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M, 2016
)
0.43

Bioavailability

Disulfiram is hardly absorbed from the cornea and its bioavailability is extremely low. This difference was concomitant with a greater inhibition of the hepatic mitochondrial high-affinity ADH activity in UChA rats.

ExcerptReferenceRelevance
"A comparison of the bioavailability of disulfiram (DSF) after administration of non-effervescent Antabuse tablets (CP Pharmaceuticals, UK) and Antabuse effervescent tablets Antabuse (A/S Dumex, DK) has been made in two cross-over studies."( Lack of bioequivalence between disulfiram formulations. Exemplified by a tablet/effervescent tablet study.
Andersen, MP, 1992
)
0.84
" This difference was concomitant with a greater inhibition of the hepatic mitochondrial high-affinity ADH activity in UChA rats than in UChB ones, whether disulfiram was administered in vivo or in vitro, which excluded the possibility that the strain difference would be caused by a different bioavailability of disulfiram."( Effect of diet and disulfiram on acetaldehyde blood levels after ethanol in UChA and UChB rats.
Quintanilla, ME; Sepúlveda, S; Tampier, L,
)
0.66
" AC-DDTC was well absorbed after oral administration."( Fate and distribution of [14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats.
Bertram, B; Lee, BH; Park, J; Ryu, JC; Wiessler, M, 1995
)
0.5
" However, disulfiram is hardly absorbed from the cornea and its bioavailability is extremely low."( Preparation and in vivo ocular absorption studies of disulfiram solid dispersion.
Cai, H; Hori, R; Ito, Y; Nabekura, T; Terao, M, 2000
)
0.96
" This system increases both the drug solubility in aqueous eye drops and the permeability of drug into the rabbit eye, by the formation of a drug-cyclodextrin inclusion complex, and so enhances the ocular bioavailability and anti-cataract effect of DSF."( Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Ito, Y; Li, D; Nabekura, T; Wang, S; Wu, C; Zhang, J, 2004
)
0.54
" The ocular bioavailability was calculated by a transcorneal experiment of DSF in vivo."( Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Ito, Y; Li, D; Nabekura, T; Wang, S; Wu, C; Zhang, J, 2004
)
0.54
"The formation of DSF/HPbetaCD inclusion and the addition of hydroxypropylmethylcellulose (HPMC), as a penetration enhancer, played very important roles in increasing the ocular bioavailability of DSF."( Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Ito, Y; Li, D; Nabekura, T; Wang, S; Wu, C; Zhang, J, 2004
)
0.54
" DSF ocular bioavailability in rabbit aqueous humor exceeded those reported for the DSF ophthalmic preparation."( Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Ito, Y; Li, D; Nabekura, T; Wang, S; Wu, C; Zhang, J, 2004
)
0.54
"Disulfiram, an alcohol antagonistic drug has been on the market since 1949 with 80% bioavailability and an established safety profile."( Antifungal potential of disulfiram.
Khan, S; Mathur, T; Rattan, A; Singhal, S; Upadhyay, DJ, 2007
)
2.09
" We examined the effects of elevated acetaldehyde within the gastrointestinal tract on the permeability and bioavailability of hydrophilic markers and drug molecules of variable molecular weight and geometry."( The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo.
Eddington, ND; Fisher, SJ; Swaan, PW, 2010
)
0.36
" Increasing numbers of new drugs are falling into class II of the Biopharmaceutical Classification System (BCS), where they have a low solubility and high tissue permeability, meaning that bioavailability is solubility dependent."( Preparation and characterisation of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram.
McConville, C; Ramadhani, N; Shabir, M, 2014
)
0.61
" Unfortunately, Cu-DSF was not orally bioavailable due to its lipophilicity."( [Development of a therapeutic agent for Menkes disease: solubilization of a copper-disulfiram complex].
Hoshi, Y; Kodama, H; Maruyama, K; Munakata, M; Natsugari, H; Oshitari, T; Tabata, H; Takahashi, H; Tani, N; Wakamatsu, S, 2015
)
0.64
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Both disulfiram (tetraethylthiuram disulfide) and thiram, a widely used pesticide, significantly increased the dopamine pool in the adrenal glands of dosed rats. Although in other respects the method is superior to surgical implants, modification of dosage and vehicle will be necessary.

ExcerptRelevanceReference
" DENA, which was administered to 38 rats in a dosage of 20 mg/kg/week, induced liver tumors in 90% of the animals; in 29% besides some precancerous stages predominantly malignant carcinomas of the oesophagus were seen."( Influence of disulfiram on the organotropy of the carcinogenic effect of dimethylnitrosamine and diethylnitrosamine in rats.
Diehl, B; Habs, M; Krüger, FW; Schmähl, D, 1976
)
0.62
" As disulfiram treatment may cause severe side effects it is recommended that the lowest possible dosage by employed."( [Disulfiram neuropathy].
Klugkist, H; Preuss, S, 1992
)
1.75
"The object of this early Phase 2 study was to determine the dosage of depot disulfiram (DSF) required to induce sustained sensitivity to alcohol."( Dose-ranging study of depot disulfiram in alcohol abusers.
Greenberg, J; Phillips, M, 1992
)
0.81
" In human volunteers treated with increasing doses of DSF and challenged with ethanol between each of the dosage periods, the mean plasma concentrations of Me-DTC at steady state were proportional to the DSF doses given."( A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites.
Johansson, B, 1992
)
0.53
" If problems with absorption and appropriate dosing of disulfiram can be resolved or a depot preparation of the active metabolite of disulfiram can be prepared, implants might find continued clinical use."( Depot preparations of disulfiram: experimental and clinical results.
Johnsen, J; Mørland, J, 1992
)
0.85
" Adequate dosage is important and the recommended maximum in some countries is often insufficient."( Controlled trials of Antabuse in alcoholism: the importance of supervision and adequate dosage.
Brewer, C, 1992
)
0.28
"The aim of this study was to investigate the relation between Antabus dosage and the disulfiram-alcohol reaction (DAR) after ethanol challenge."( Dose-effect relationship of disulfiram in human volunteers. I: Clinical studies.
Angelo, HR; Christensen, JK; Johansson, B; Møller, IW; Rønsted, P, 1991
)
0.8
" Thus no change in acetaminophen dosage would be required in patients treated with disulfiram."( The influence of disulfiram on acetaminophen metabolism in man.
Jørgensen, L; Poulsen, HE; Ranek, L, 1991
)
0.85
" Cardiac, hepatic, and neurologic toxicity can also occur within this dosage range."( Disulfiram treatment of alcoholism.
Moore, RD; Wright, C, 1990
)
1.72
"Severe hypotension resulting from a disulphiram-ethanol reaction was treated with adrenaline, the maximum dosage being 170 micrograms/kg/hour."( [High-dose adrenaline in the treatment of severe hypotensive crisis caused by a disulfiram-ethanol reaction].
Møller, LM; Pedersen, B, 1990
)
0.51
" The degree of ALDH inhibition from 8 to 172 hr after dosing was the same for all three drugs."( Comparative aspects of disulfiram and its metabolites in the disulfiram-ethanol reaction in the rat.
Faiman, MD; Yourick, JJ, 1989
)
0.59
" Hence, a useful dose-response curve for this drug cannot be determined easily."( Serum albumin and the metabolism of disulfiram.
Agarwal, RP; Hensley, P; McPherson, RA; Phillips, M, 1986
)
0.55
" Although in other respects the method is superior to surgical implants, modification of dosage and vehicle will be necessary, and the high incidence and severity of side effects preclude further clinical use of disulfiram in this form."( Assessment of intramuscular emulsified disulfiram in alcoholics by estimation of urinary diethylamine.
Carey-Smith, KA; Irvine, BL; Joll, TA; Nyoni, VS, 1988
)
0.73
" This paper reviews the evidence for its effectiveness, emphasizes the importance of correct dosage and supervised administration and of viewing disulfiram as generally only one component of treatment."( Supervised disulfiram in alcoholism.
Brewer, C, 1986
)
0.86
" In most cases it was possible to out-manoeuvre the patients by increasing the dosage or modifying the supervision techniques."( Patterns of compliance and evasion in treatment programmes which include supervised disulfiram.
Brewer, C, 1986
)
0.5
" Pretreatment of animals with pyrazole (400 mg/kg, ip) 1 hr prior to [14C]ME dosing gave complete protection against the testicular toxicity of ME."( The role of metabolism in 2-methoxyethanol-induced testicular toxicity.
Cook, MW; Creasy, DM; Foster, PM; Gray, TJ; Moss, EJ; Thomas, LV; Walters, DG, 1985
)
0.27
"3% of the disulfiram after single and repeated dosing was eliminated in the breath during one dosing interval."( Elimination kinetics of disulfiram in alcoholics after single and repeated doses.
Faiman, MD; Jensen, JC; Lacoursiere, RB, 1984
)
0.98
" Although all groups showed an increase in sobriety following implantation, there was no significant dose-response relationship."( Disulfiram implantation: a dose response trial.
Blanchard, R; Davidson, W; Maini, K; McRae, L; Wilson, A, 1984
)
1.71
" Oral administration of disulfiram tablets starting with 50 mg a day with a gradual increase in dosage to 100 mg more than than twice a day readily cleared the eczema in three patients with severe and long-standing nickel contact dermatitis."( Disulfiram treatment of three patients with nickel dermatitis.
Christensen, JD, 1982
)
2.01
" Despite continued disulfiram in decreased dosage (125 mg daily), associated with multivitamin supplementation, marked improvement in symptoms and signs was noted, contrary to previous case reports."( Peripheral neuropathy after disulfiram administration: reversibility despite continued therapy.
Worner, TM,
)
0.75
" Disulfiram was administered at a dosage of 125 mg/day for seven days and 250 mg/day thereafter for 36 weeks."( Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study.
Charuvastra, VC; Ling, W; O'Brien, CP; Weiss, DG, 1983
)
1.63
"5 g daily but even at high dosage significant side effects are uncommon, reversible and rarely serious."( How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice.
Brewer, C, 1984
)
0.54
" Dose-response curves have been obtained for the 17 most active compounds."( Screening of antioxidants and other compounds for antimutagenic properties towards benzo[a]pyrene-induced mutagenicity in strain TA98 of Salmonella typhimurium.
Calle, LM; Sullivan, PD, 1982
)
0.26
"The colorimetric reaction of cuprous iodide and disulfiram has been collaboratively studied in 8 laboratories to determine the drug in tablet form at 2 dosage levels."( Colorimetric determination of disulfiram in tablets: collaborative study.
Hanus, JP; Johnson, RH; Lazar, A; Newton, JM; Olsen, RE; Petzinger, G; Ristich, R; Robinette, ML; Wojtowicz, EJ, 1981
)
0.81
" Short-term administration of a moderate daily dosage of PYZ also inhibited endogenous EP-ALDH from saline controls."( Epididymal aldehyde dehydrogenase: a pharmacologic profile.
Messiha, FS, 1981
)
0.26
" Eleven patients with chronic nickel hand dermatitis were given a daily dosage of 200 to 400 mg of tetraethylthiuramdisulfide (Antabuse)."( Treatment of nickel dermatitis. (The influence of tetraethylthiuramdisulfide (Antabuse) on nickel metabolism).
Kaaber, K; Menne, T; Tjell, JC,
)
0.13
" It was also shown that a discontinuous dosage of disulfiram protects against the alkylating effect of 14C nitrosodiethylamine only for a distinct period of time."( Effect of disulfiram on the alkylation of rat liver DNA by nitrosodiethylamine.
Bertram, B; Frank, N; Hadjiolov, D; Wiessler, M, 1980
)
0.92
" A dose-response study revealed that approximately twice the dose of DDTC was required in mice to cause the same olfactory toxic effects seen in the rat."( Olfactory toxicity of diethyldithiocarbamate (DDTC) and disulfiram and the protective effect of DDTC against the olfactory toxicity of dichlobenil.
Deamer, NJ; Genter, MB, 1995
)
0.54
" Male Sprague-Dawley rats were dosed with either 375, 750 or 1500 mg/kg disulfiram via oral intubation for 1, 3 and 6 weeks."( The effects of disulfiram on the hippocampus and cerebellum of the rat brain: a study on oxidative stress.
Delmaestro, E; Trombetta, LD, 1995
)
0.88
" In order to investigate the nature of such electrophilic intermediates in vivo, the present study was carried out with the goal of detecting and identifying their respective glutathione (GSH) conjugates in the bile of rats dosed ip with either disulfiram (75 mg kg-1) or sodium DDTC (114 mg kg-1)."( Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography-tandem mass spectrometry. Evidence for metabolic activation of disulfiram in vivo.
Baillie, TA; Davis, MR; Hu, P; Jin, L,
)
0.57
"48 mmol/kg) followed by oral dosing with ME (2."( Methoxyacetaldehyde, an intermediate metabolite of 2-methoxyethanol, is immunosuppressive in the rat.
Riddle, MM; Smialowicz, RJ; Williams, WC, 1993
)
0.29
"Of 60 depressed alcoholics who completed an open trial of imipramine, 27 (45%) responded with improvement in both mood and drinking behavior, and eight (13%) responded after further dosage increases or treatment with disulfiram."( Imipramine treatment of alcoholism with comorbid depression.
Harrison, W; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JP; Tricamo, E, 1993
)
0.47
"Both disulfiram (tetraethylthiuram disulfide), an alcohol aversive drug, and thiram (tetramethyl-thiuram disulfide), a widely used pesticide, significantly increased the dopamine pool in the adrenal glands of dosed rats."( Comparative effects of two dithiocarbamates disulfiram and thiram, on adrenal catecholamine content and on plasma dopamine-beta-hydroxylase activity.
Caroldi, S; De Paris, P, 1995
)
1.07
" Besides adequate dosage and formulation of substance, the Antabuse tablet has to be taken under supervision by a therapist to strengthen compliance and motivate the patient to continue long-term treatment."( How to get the best out of antabuse.
Kristenson, H, 1995
)
0.29
" We thus suggest the following protocol: 1) physical examination and interview 3-4 weeks after initiation of treatment; 2) as a general rule, in abstinent patients, the lowest possible maintenance dosage should be administered."( [Collateral effects of disulfiram on the central nervous system in alcoholics that have become totally abstemious. Description of 8 cases].
Fornaciari, G; Giglioli, W; Maccari, S; Semrov, E,
)
0.44
" In our study, rats were dosed with either disulfiram (0."( Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N-acetylcysteine conjugates.
Baillie, TA; Hu, P; Jin, L, 1997
)
0.83
" They also received the experimental diets containing one of test compounds (500 ppm) for 5 weeks, starting one week before the first dosing of AOM."( Inhibition of azoxymethane-induced aberrant crypt foci in rats by natural compounds, caffeine, quercetin and morin.
Honjo, S; Kawabata, K; Kohno, H; Matsunaga, K; Murakami, M; Shimada, R; Shimizu, M; Tanaka, T; Yamada, Y,
)
0.13
" Rats were dosed with BHA, butylated hydroxytoluene (BHT), ethoxyquin (EQ), dimethyl fumarate (DMF) or disulfiram (DIS) and then challenged with a toxic dose of the naphthoquinones."( Effect of inducers of DT-diaphorase on the toxicity of 2-methyl- and 2-hydroxy-1,4-naphthoquinone to rats.
Munday, CM; Munday, R; Smith, BL, 1999
)
0.52
"We examined the effects of Dbh gene dosage and the DBH inhibitor disulfiram in mice with zero, one, or two null Dbh alleles (+/+, +/-, and-/- mice)."( Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice.
Anderson, GM; Bonsall, RW; Bourdélat-Parks, BN; Donaldson, ZR; Emery, MS; Liles, LC; Weinshenker, D; Weiss, JM, 2005
)
0.82
" Over time, he increased the dosage to 50 tablets daily (3750 mg)."( Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse.
Lugoboni, F; Quaglio, G; Schifano, F, 2008
)
0.35
" Both decreased cellular proliferation and increased apoptosis were seen at 50-500 nmol/l DSF concentrations that are achievable through oral dosing of the medication."( Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.
Doudican, NA; Morrison, BW; Orlow, SJ; Patel, KR, 2010
)
1.8
" The methodology was utilized to demonstrate the carbamathione plasma-time profile of a human volunteer dosed with disulfiram (250 mg/d)."( LC-MS/MS method for the determination of carbamathione in human plasma.
Faiman, MD; Heemskerk, AA; McCance-Katz, EF; Stobaugh, JF; van Haandel, L; Williams, TD; Woods, JM, 2011
)
0.58
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Our results suggest that the use of weight-based medication doses would produce more reliable effects, consistent with weight-based dosing used in pediatrics and in preclinical research."( The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial.
De La Garza, R; Haile, CN; Kosten, TR; Mahoney, JJ; Newton, TF; Nielsen, DA, 2012
)
0.74
"Escalating the disulfiram dosage caused a biphasic reduction in the surviving fraction of clonogens."( The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells.
Babich, JW; Boyd, M; Mairs, RJ; Rae, C; Sorensen, A; Tesson, M, 2013
)
1.06
" For prostate cancer, dose-response analyses showed a further risk reduction with the highest cumulative dose level of disulfiram; however, the test for trend did not reach statistical significance."( Use of disulfiram and risk of cancer: a population-based case-control study.
Askgaard, G; Friis, S; Hallas, J; Pottegård, A; Thygesen, LC, 2014
)
1.07
"Female CD2F1 mice were dosed with 20 mg/kg BEN iv alone or 24 h after 300 mg/kg disulfiram ip."( Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.
Beumer, JH; Clausen, DM; Eiseman, JL; Gasparetto, M; Parise, RA; Rigatti, LH; Smith, CA; Ziegler, JA, 2013
)
0.87
" However, in combination studies, pretreatment with either disulfiram or nepicastat produced leftward shifts in the cocaine dose-response function and also conferred cocaine-like stimulus effects to the selective NE transporter inhibitor, reboxetine (0."( Dopamine β-hydroxylase inhibitors enhance the discriminative stimulus effects of cocaine in rats.
DePoy, LM; Manvich, DF; Weinshenker, D, 2013
)
0.63
" These tablets were tested in accordance with the European Pharmacopeia testing of solid dosage form guidelines."( Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer.
Baffoe, CS; Boyd, P; McConville, C; Morris, M; Nguyen, N; Wang, W, 2015
)
1.86
"We have developed both immediate and sustained release vaginal tablets, which when manufactured at pilot scale are within the limits set by the European Pharmacopeia for the testing of solid dosage forms."( Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer.
Baffoe, CS; Boyd, P; McConville, C; Morris, M; Nguyen, N; Wang, W, 2015
)
1.86
" Participants were allocated sequentially to one of three dosing groups (500 mg, 1000 mg, and 2000 mg) and received disulfiram daily for 3 days."( Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.
Bacchetti, P; Bumpus, N; Chang, CC; Deeks, SG; Elliott, JH; Gorelick, RJ; Hartogensis, W; Hoh, R; Lee, SA; Lewin, SR; Lifson, J; McMahon, JH; Piatak, M; Roney, J; Savic, R; Solomon, A, 2015
)
0.92
" Our results suggest that DSF alone contributes to cell death, while polysorbate 80-stabilized PLGA nanoparticles show sustained drug release patterns that would potentially lower dosage regimens."( Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line.
Hoda, M; Mohankumar, K; Pajaniradje, S; Rajagopalan, R; Shakya, G, 2016
)
0.68
" The authors report a unique case of an extremely severe axonal polyneuropathy involving cranial nerves that developed within weeks after a regular dosage of 500mg/day disulfiram."( Sensory-motor axonal polyneuropathy involving cranial nerves: An uncommon manifestation of disulfiram toxicity.
Martins Campos, A; Morais, H; Santos, T, 2017
)
0.87
"6 mg/kg) produced a significant downward shift in the d-methamphetamine dose-response function; surprisingly, lower and higher pretreatment doses (3."( Limited modulation of the abuse-related behavioral effects of d-methamphetamine by disulfiram.
Bergman, J; de Moura, FB; Kohut, SJ, 2018
)
0.71
"Using patient-derived glioblastoma stem cell (GSC) cultures from 15 GBM patients, we described stem cell properties of individual cultures, determined the dose-response relationships of the drugs in the CUSP9, and assessed the efficacy the CUSP9 combination with TMZ in concentrations clinically achievable."( The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019
)
0.51
" The dose-response assays, XTT assays, scanning electron microscopy and confocal laser scanning microscopy were used to confirm the antifungal activities of the selected compounds against Candida strains."( Identification of disulfiram as a potential antifungal drug by screening small molecular libraries.
Du, N; Fan, Y; Ge, X; Han, Y; Hao, W; Li, X; Qiao, D; Zhang, H, 2021
)
0.96
"Through the primary screening, we identified five compounds (U73122, disulfiram, BSK805, BIX01294, and GSKJ4) that inhibited strains growth ≥ 80% for dose-response assays."( Identification of disulfiram as a potential antifungal drug by screening small molecular libraries.
Du, N; Fan, Y; Ge, X; Han, Y; Hao, W; Li, X; Qiao, D; Zhang, H, 2021
)
1.19
" A synergistic treatment with drug supporting activity could maximize the cytotoxic effects of chemotherapeutic agents on tumor cells while decreasing the dosage of each drug to potentially reduce toxicity."( Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death.
Guo, F; Kaufmann, AM; Sehouli, J; Yang, Z, 2022
)
0.72
" This approach provides a local treatment modality, which inevitably decreases dosing frequency and improves patient compliance."( Disulfiram 3D printed film produced via hot-melt extrusion techniques as a potential anticervical cancer candidate.
Almotairy, A; Almutairi, M; Althobaiti, A; Alyahya, M; Ashour, EA; Bandari, S; Repka, MA, 2023
)
2.35
" Development strategies using molecular encapsulation of DS and the parenteral dosage forms improve the anticancer pharmacology of the drug."( Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review.
Benkő, BM; Lamprou, DA; Sebe, I; Sebestyén, A; Zelkó, R, 2023
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (10)

RoleDescription
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitorAn EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of aldehyde dehydrogenase (NAD(+)), EC 1.2.1.3.
angiogenesis inhibitorAn agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
EC 3.1.1.8 (cholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8).
EC 3.1.1.1 (carboxylesterase) inhibitorAny EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of carboxylesterase (EC 3.1.1.1 ).
EC 5.99.1.2 (DNA topoisomerase) inhibitorA topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.
fungicideA substance used to destroy fungal pests.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
NF-kappaB inhibitorAn inhibitor of NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), a protein complex involved in the transcription of DNA.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
ferroptosis inducerAny substance that induces or promotes ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic disulfideCompounds of structure RSSR in which R and R' are organic groups.
organosulfur acaricide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Programmed Cell Death17012
Regulated Necrosis389
Disulfiram Action Pathway2366
Pyroptosis152
4-aminobutyrate degradation220
4-aminobutanoate degradation I720
GABA shunt623

Protein Targets (215)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.79430.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency65.81140.044717.8581100.0000AID485294; AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency18.82300.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency14.26470.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency14.26470.025120.237639.8107AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency30.30015.623417.292931.6228AID2323; AID485281
Chain A, CruzipainTrypanosoma cruziPotency11.66980.002014.677939.8107AID1476; AID1478
LuciferasePhotinus pyralis (common eastern firefly)Potency10.16590.007215.758889.3584AID1224835; AID588342; AID624030
acetylcholinesteraseHomo sapiens (human)Potency61.45340.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
thioredoxin reductaseRattus norvegicus (Norway rat)Potency18.89260.100020.879379.4328AID488773; AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency0.32080.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency3.13050.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency0.40623.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.21190.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency0.19950.173734.304761.8120AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency17.03430.004110.890331.5287AID493106; AID493107; AID504467
Fumarate hydrataseHomo sapiens (human)Potency19.48720.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency29.34910.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency7.07950.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency21.09810.35487.935539.8107AID624146; AID624170
PPM1D proteinHomo sapiens (human)Potency14.74030.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency0.19950.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency0.07220.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.36520.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency6.17540.180013.557439.8107AID1460; AID1468
ThrombopoietinHomo sapiens (human)Potency0.39810.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency1.87270.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency0.10000.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency14.12540.707912.194339.8107AID720542
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency11.42640.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.16960.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency0.19040.000657.913322,387.1992AID1259377; AID1259378
hypothetical protein, conservedTrypanosoma bruceiPotency9.94290.223911.245135.4813AID624147; AID624173
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency1.60770.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency1.70730.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency1.06210.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency21.21310.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency0.03890.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency3.31170.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency31.35400.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.25520.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency18.26710.000817.505159.3239AID1159527; AID1159531; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.19990.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency0.11240.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency26.19920.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency11.11420.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency6.45500.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency16.28010.00108.379861.1304AID1645840
polyproteinZika virusPotency19.48720.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.31380.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency13.39650.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency18.64340.023723.228263.5986AID588541; AID588543; AID743222; AID743223; AID743241
pyruvate kinaseLeishmania mexicana mexicanaPotency15.84890.398113.744731.6228AID945; AID959
caspase-3Homo sapiens (human)Potency11.42640.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency0.01300.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.75890.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency51.02820.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.09060.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency44.71770.001628.015177.1139AID1224843; AID1224895; AID1259385
activating transcription factor 6Homo sapiens (human)Potency0.62700.143427.612159.8106AID1159516
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency23.52670.154917.870243.6557AID1346877; AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.472919.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency2.20650.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency1.12190.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency10.55890.006723.496068.5896AID1346980
beta-2 adrenergic receptorHomo sapiens (human)Potency0.65130.00586.026332.6427AID492947
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency11.995523.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency22.53580.316212.443531.6228AID902; AID924
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency2.90191.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency2.90310.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.45500.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency3.26410.02245.944922.3872AID488982
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency3.12720.001815.663839.8107AID894
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency2.39340.134610.395030.1313AID1347049
runt-related transcription factor 1 isoform AML1bHomo sapiens (human)Potency0.53810.02007.985839.8107AID504370; AID504374
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency5.16330.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency22.98330.006026.168889.1251AID488953; AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency2.81840.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency10.55890.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency5.74340.000323.4451159.6830AID743065; AID743066; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency11.12550.037617.082361.1927AID1259364
heat shock protein beta-1Homo sapiens (human)Potency0.18140.042027.378961.6448AID743210; AID743228
core-binding factor subunit beta isoform 2Homo sapiens (human)Potency0.53810.02007.985839.8107AID504370; AID504374
huntingtin isoform 2Homo sapiens (human)Potency0.79430.000618.41981,122.0200AID1688
polypyrimidine tract-binding protein 1 isoform aHomo sapiens (human)Potency14.55003.981115.308231.6228AID2730; AID2733
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency5.21190.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency0.73600.00378.618923.2809AID2660; AID2666; AID2668
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency0.84370.168316.404067.0158AID720504
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency39.81070.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency10.69510.000627.21521,122.0200AID720636; AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.52630.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency12.14150.004611.374133.4983AID463097; AID504364; AID624296; AID624297
VprHuman immunodeficiency virus 1Potency12.58931.584919.626463.0957AID651644
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency14.82390.005612.367736.1254AID624032; AID624044
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.57850.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency10.00000.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency22.01630.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency12.58930.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency3.98110.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.81640.891312.067628.1838AID1459; AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency25.11892.511912.262825.1189AID954; AID958
neuropeptide S receptor isoform AHomo sapiens (human)Potency19.78310.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency8.88610.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.22560.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency11.42620.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency6.45500.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency18.88050.002319.595674.0614AID651631; AID720552
Integrin beta-3Homo sapiens (human)Potency25.11890.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency25.11890.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.22560.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency5.17350.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency5.70140.00638.235039.8107AID881; AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.79430.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency15.84891.000010.475628.1838AID1457
TAR DNA-binding protein 43Homo sapiens (human)Potency3.98111.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency6.45500.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency33.33580.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency30.54510.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.57851.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency6.45500.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency12.30430.060110.745337.9330AID485367; AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonasePlasmodium bergheiIC50 (µMol)56.70000.889021.028671.5000AID504765; AID540252; AID540269
Spike glycoproteinBetacoronavirus England 1IC50 (µMol)9.35000.03002.72839.5100AID1804127
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)18.07500.00403.43889.5100AID1640022; AID1804127
type-1 angiotensin II receptorHomo sapiens (human)IC50 (µMol)6.63702.22108.230418.7980AID463214
perilipin-5Homo sapiens (human)IC50 (µMol)1.62200.98503.45659.4680AID504319
glucose-6-phosphate 1-dehydrogenase isoform bHomo sapiens (human)IC50 (µMol)80.00008.870012.851817.8000AID504792
perilipin-1Homo sapiens (human)IC50 (µMol)6.95900.92503.30339.6190AID504317
apelin receptorHomo sapiens (human)IC50 (µMol)2.63001.75003.39008.3500AID2784
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform aHomo sapiens (human)IC50 (µMol)4.29050.92503.58289.6190AID504317; AID504319
bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferaseMycobacterium tuberculosis H37RvIC50 (µMol)85.03003.910083.9944180.9200AID1376
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)363.07800.00020.59827.0000AID441698
Transmembrane protease serine 2Homo sapiens (human)IC50 (µMol)9.35000.01802.61989.5100AID1804127
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)71.50000.11007.190310.0000AID1449628; AID1473738
Carbamate kinaseGiardia intestinalisIC50 (µMol)0.60000.60000.60000.6000AID1743058
Retinal dehydrogenase 1Homo sapiens (human)IC50 (µMol)0.13000.02001.04766.7900AID1762210
Aldehyde dehydrogenase, mitochondrialHomo sapiens (human)IC50 (µMol)3.40000.04003.40799.0000AID1762211
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)4.00000.00011.774010.0000AID625245
Procathepsin LHomo sapiens (human)IC50 (µMol)9.35000.00021.66619.5100AID1804127
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)70.37000.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki69.81200.00322.28879.3160AID625207
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)4.90400.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki1.83900.00010.807410.0000AID625201
Fructose-1,6-bisphosphatase 1Homo sapiens (human)IC50 (µMol)101.23800.01002.00979.8000AID1654807; AID1654810; AID1654811; AID1654812; AID1654813; AID1654814; AID1654815; AID1654816; AID1703767; AID1893103
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)9.35000.03002.29719.5100AID1804127
Replicase polyprotein 1abHuman coronavirus 229EIC50 (µMol)9.35000.03002.14419.5100AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)9.35000.00402.92669.9600AID1804127; AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusKi3.71000.00753.00839.1100AID1805801
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)0.35600.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki0.20100.00000.930610.0000AID625196
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)6.91710.00022.45859.9600AID1640021; AID1803933; AID1804127; AID1805801; AID1845234; AID1845236; AID1884048; AID1899611; AID1899613
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2Ki3.71000.00001.63079.0000AID1805801
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)16.06600.11003.26419.0330AID625146
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)23.01800.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki7.67300.00000.651810.0000AID625253
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.35600.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.20100.00010.949010.0000AID625196
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)3.21800.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki1.46900.00020.725710.0000AID625202
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)13.73400.00002.37899.7700AID625150
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)2.15800.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki1.07900.00010.836310.0000AID625252
D(4) dopamine receptorHomo sapiens (human)IC50 (µMol)3.15000.00011.14239.3280AID625255
D(4) dopamine receptorHomo sapiens (human)Ki1.10500.00000.436210.0000AID625255
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)70.37000.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki69.81200.00031.465610.0000AID625207
C-X-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)6.01300.00000.30296.0130AID625241
C-X-C chemokine receptor type 2Homo sapiens (human)Ki4.20900.00401.05584.2090AID625241
Mitogen-activated protein kinase 3 Homo sapiens (human)IC50 (µMol)1.51000.00253.09269.5820AID625180
Protein-lysine 6-oxidaseHomo sapiens (human)IC50 (µMol)0.32000.01001.19705.0000AID1399349
Lysine-specific demethylase 5AHomo sapiens (human)IC50 (µMol)10.00000.13002.374710.0000AID1506822
Caspase-1Homo sapiens (human)IC50 (µMol)1.80000.00201.70138.8000AID1801388
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)3.51100.00010.813310.0000AID625163
Mu-type opioid receptorHomo sapiens (human)Ki1.42500.00000.419710.0000AID625163
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)1.08400.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.36800.00000.602010.0000AID625254
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)6.10300.00001.201110.0000AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki2.44100.00000.362410.0000AID625162
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)34.54700.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki21.98400.00030.769310.0000AID625217
C-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)2.46800.00000.67366.6990AID625237
C-C chemokine receptor type 2Homo sapiens (human)Ki0.95400.00200.84276.3096AID625237
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.35600.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.20100.00000.965010.0000AID625196
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)16.00100.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki7.42900.00020.522910.0000AID625221
C-C chemokine receptor type 4Homo sapiens (human)IC50 (µMol)8.39500.20004.542410.0000AID625238
C-C chemokine receptor type 4Homo sapiens (human)Ki4.39704.39704.39704.3970AID625238
C-C chemokine receptor type 5Homo sapiens (human)IC50 (µMol)23.66100.00020.25679.0000AID625239
C-C chemokine receptor type 5Homo sapiens (human)Ki18.28400.00210.23060.8520AID625239
Gasdermin-DHomo sapiens (human)IC50 (µMol)0.40000.40000.40000.4000AID1525286
Lysyl oxidase homolog 3Homo sapiens (human)IC50 (µMol)0.09300.09300.17080.3100AID1399351
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusIC50 (µMol)9.35000.03002.77319.5100AID1804127
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)4.63700.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki3.68400.00021.11158.0280AID625256
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)IC50 (µMol)3.00000.00041.441910.0000AID1759582
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Lysyl oxidase homolog 4Homo sapiens (human)IC50 (µMol)0.05900.05900.11950.1800AID1399352
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)IC50 (µMol)0.60000.00251.14809.2000AID1374899
Monoglyceride lipaseHomo sapiens (human)IC50 (µMol)0.80950.00091.126810.0000AID1363916; AID441697
Angiotensin-converting enzyme 2 Homo sapiens (human)IC50 (µMol)9.35000.00042.207910.0000AID1804127
Gasdermin-DMus musculus (house mouse)IC50 (µMol)0.40000.40000.40000.4000AID1525287
Histone-lysine N-methyltransferase EHMT1Homo sapiens (human)IC50 (µMol)1.60000.01300.79954.9000AID1374900
Lysyl oxidase homolog 2Homo sapiens (human)IC50 (µMol)0.15000.06600.56494.2600AID1399350
large T antigenBetapolyomavirus macacaeIC50 (µMol)10.73000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)3.00000.00033.166210.0000AID482138
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC505.17800.19503.667918.6960AID540270
heat shock protein 90, putativePlasmodium falciparum 3D7AC504.55400.19504.992098.5000AID540268
hypothetical protein CAALFM_CR05890CACandida albicans SC5314AC503.26001.550013.003854.7000AID588764
H3 histone acetyltransferaseCandida albicans SC5314AC503.26001.550013.003854.7000AID588764
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (963)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
retinoid metabolic processRetinal dehydrogenase 1Homo sapiens (human)
cellular aldehyde metabolic processRetinal dehydrogenase 1Homo sapiens (human)
gamma-aminobutyric acid biosynthetic processRetinal dehydrogenase 1Homo sapiens (human)
fructosamine catabolic processRetinal dehydrogenase 1Homo sapiens (human)
maintenance of lens transparencyRetinal dehydrogenase 1Homo sapiens (human)
retinol metabolic processRetinal dehydrogenase 1Homo sapiens (human)
cellular detoxification of aldehydeRetinal dehydrogenase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisRetinal dehydrogenase 1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
carbohydrate metabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
alcohol metabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
ethanol catabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
aldehyde catabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
regulation of dopamine biosynthetic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
regulation of serotonin biosynthetic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose 6-phosphate metabolic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
gluconeogenesisFructose-1,6-bisphosphatase 1Homo sapiens (human)
regulation of gluconeogenesisFructose-1,6-bisphosphatase 1Homo sapiens (human)
dephosphorylationFructose-1,6-bisphosphatase 1Homo sapiens (human)
negative regulation of cell growthFructose-1,6-bisphosphatase 1Homo sapiens (human)
response to nutrient levelsFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to insulin stimulusFructose-1,6-bisphosphatase 1Homo sapiens (human)
negative regulation of glycolytic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
negative regulation of Ras protein signal transductionFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to magnesium ionFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to cAMPFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to xenobiotic stimulusFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular hyperosmotic salinity responseFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular hypotonic salinity responseFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to raffinoseFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose 1,6-bisphosphate metabolic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose metabolic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
sucrose biosynthetic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-X-C chemokine receptor type 2Homo sapiens (human)
signal transductionC-X-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cell population proliferationC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil activationC-X-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 2Homo sapiens (human)
immune responseC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 3 Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-templated transcriptionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 3 Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 3 Homo sapiens (human)
phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
sensory perception of painMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 3 Homo sapiens (human)
BMP signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 3 Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 3 Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 3 Homo sapiens (human)
peptidyl-tyrosine autophosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
myelinationMitogen-activated protein kinase 3 Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 3 Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 3 Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 3 Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 3 Homo sapiens (human)
cartilage developmentMitogen-activated protein kinase 3 Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 3 Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 3 Homo sapiens (human)
face developmentMitogen-activated protein kinase 3 Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
trachea formationMitogen-activated protein kinase 3 Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 3 Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 3 Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 3 Homo sapiens (human)
xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
negative regulation of TORC1 signalingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 3 Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 3 Homo sapiens (human)
osteoblast differentiationProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of protein phosphorylationProtein-lysine 6-oxidaseHomo sapiens (human)
heart developmentProtein-lysine 6-oxidaseHomo sapiens (human)
response to xenobiotic stimulusProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of gene expressionProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of striated muscle tissue developmentProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
peptidyl-lysine oxidationProtein-lysine 6-oxidaseHomo sapiens (human)
bone mineralizationProtein-lysine 6-oxidaseHomo sapiens (human)
lung developmentProtein-lysine 6-oxidaseHomo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
ascending aorta developmentProtein-lysine 6-oxidaseHomo sapiens (human)
descending aorta developmentProtein-lysine 6-oxidaseHomo sapiens (human)
protein modification processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of apoptotic processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of megakaryocyte differentiationProtein-lysine 6-oxidaseHomo sapiens (human)
muscle cell cellular homeostasisProtein-lysine 6-oxidaseHomo sapiens (human)
elastic fiber assemblyProtein-lysine 6-oxidaseHomo sapiens (human)
blood vessel morphogenesisProtein-lysine 6-oxidaseHomo sapiens (human)
response to steroid hormoneProtein-lysine 6-oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProtein-lysine 6-oxidaseHomo sapiens (human)
muscle cell developmentProtein-lysine 6-oxidaseHomo sapiens (human)
cell chemotaxisProtein-lysine 6-oxidaseHomo sapiens (human)
connective tissue developmentProtein-lysine 6-oxidaseHomo sapiens (human)
DNA biosynthetic processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of bone developmentProtein-lysine 6-oxidaseHomo sapiens (human)
cellular response to chemokineProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of platelet-derived growth factor receptor-beta signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
collagen fibril organizationProtein-lysine 6-oxidaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific demethylase 5AHomo sapiens (human)
circadian regulation of gene expressionLysine-specific demethylase 5AHomo sapiens (human)
positive regulation of DNA-templated transcriptionLysine-specific demethylase 5AHomo sapiens (human)
regulation of DNA-binding transcription factor activityLysine-specific demethylase 5AHomo sapiens (human)
facultative heterochromatin formationLysine-specific demethylase 5AHomo sapiens (human)
regulation of DNA-templated transcriptionLysine-specific demethylase 5AHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 5AHomo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
blood vessel remodelingC-C chemokine receptor type 2Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell cytokine productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of type 2 immune responseC-C chemokine receptor type 2Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
humoral immune responseC-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of adenylate cyclase activityC-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATC-C chemokine receptor type 2Homo sapiens (human)
response to woundingC-C chemokine receptor type 2Homo sapiens (human)
regulation of vascular endothelial growth factor productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of angiogenesisC-C chemokine receptor type 2Homo sapiens (human)
sensory perception of painC-C chemokine receptor type 2Homo sapiens (human)
cellular homeostasisC-C chemokine receptor type 2Homo sapiens (human)
hemopoiesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of type II interferon productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of interleukin-2 productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionC-C chemokine receptor type 2Homo sapiens (human)
monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
T-helper 17 cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of eosinophil degranulationC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell differentiationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of alpha-beta T cell proliferationC-C chemokine receptor type 2Homo sapiens (human)
homeostasis of number of cells within a tissueC-C chemokine receptor type 2Homo sapiens (human)
regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell activationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicC-C chemokine receptor type 2Homo sapiens (human)
leukocyte adhesion to vascular endothelial cellC-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of immune complex clearance by monocytes and macrophagesC-C chemokine receptor type 2Homo sapiens (human)
inflammatory response to woundingC-C chemokine receptor type 2Homo sapiens (human)
neutrophil clearanceC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cold-induced thermogenesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of leukocyte tethering or rollingC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of NMDA glutamate receptor activityC-C chemokine receptor type 2Homo sapiens (human)
macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
regulation of macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of thymocyte migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of CD8-positive, alpha-beta T cell extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of astrocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of hematopoietic stem cell migrationC-C chemokine receptor type 2Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
immune responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 2Homo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
tolerance inductionC-C chemokine receptor type 4Homo sapiens (human)
chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 4Homo sapiens (human)
response to bacteriumC-C chemokine receptor type 4Homo sapiens (human)
homeostasis of number of cellsC-C chemokine receptor type 4Homo sapiens (human)
positive regulation of positive chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 4Homo sapiens (human)
interneuron migrationC-C chemokine receptor type 4Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 4Homo sapiens (human)
immune responseC-C chemokine receptor type 4Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 4Homo sapiens (human)
MAPK cascadeC-C chemokine receptor type 5Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 5Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 5Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulumC-C chemokine receptor type 5Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 5Homo sapiens (human)
signalingC-C chemokine receptor type 5Homo sapiens (human)
symbiont entry into host cellC-C chemokine receptor type 5Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
response to cholesterolC-C chemokine receptor type 5Homo sapiens (human)
cellular response to lipopolysaccharideC-C chemokine receptor type 5Homo sapiens (human)
negative regulation of macrophage apoptotic processC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 5Homo sapiens (human)
immune responseC-C chemokine receptor type 5Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseGasdermin-DHomo sapiens (human)
protein secretionGasdermin-DHomo sapiens (human)
positive regulation of interleukin-1 beta productionGasdermin-DHomo sapiens (human)
innate immune responseGasdermin-DHomo sapiens (human)
pore complex assemblyGasdermin-DHomo sapiens (human)
positive regulation of inflammatory responseGasdermin-DHomo sapiens (human)
defense response to Gram-negative bacteriumGasdermin-DHomo sapiens (human)
defense response to Gram-positive bacteriumGasdermin-DHomo sapiens (human)
protein homooligomerizationGasdermin-DHomo sapiens (human)
transmembrane transportGasdermin-DHomo sapiens (human)
pyroptosisGasdermin-DHomo sapiens (human)
defense response to bacteriumGasdermin-DHomo sapiens (human)
epithelial to mesenchymal transitionLysyl oxidase homolog 3Homo sapiens (human)
inflammatory responseLysyl oxidase homolog 3Homo sapiens (human)
peptidyl-lysine oxidationLysyl oxidase homolog 3Homo sapiens (human)
spinal cord developmentLysyl oxidase homolog 3Homo sapiens (human)
lung developmentLysyl oxidase homolog 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionLysyl oxidase homolog 3Homo sapiens (human)
roof of mouth developmentLysyl oxidase homolog 3Homo sapiens (human)
somite developmentLysyl oxidase homolog 3Homo sapiens (human)
fibronectin fibril organizationLysyl oxidase homolog 3Homo sapiens (human)
negative regulation of T-helper 17 cell lineage commitmentLysyl oxidase homolog 3Homo sapiens (human)
positive regulation of integrin-mediated signaling pathwayLysyl oxidase homolog 3Homo sapiens (human)
collagen fibril organizationLysyl oxidase homolog 3Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
collagen fibril organizationLysyl oxidase homolog 4Homo sapiens (human)
peptidyl-lysine oxidationLysyl oxidase homolog 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to starvationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of DNA replicationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
synaptonemal complex assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
spermatid developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
long-term memoryHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
fertilizationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of protein modification processHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
organ growthHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
phenotypic switchingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
behavioral response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
oocyte developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
neuron fate specificationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to xenobiotic stimulusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of autophagosome assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
lipid metabolic processMonoglyceride lipaseHomo sapiens (human)
fatty acid biosynthetic processMonoglyceride lipaseHomo sapiens (human)
inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of signal transductionMonoglyceride lipaseHomo sapiens (human)
arachidonic acid metabolic processMonoglyceride lipaseHomo sapiens (human)
triglyceride catabolic processMonoglyceride lipaseHomo sapiens (human)
acylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of sensory perception of painMonoglyceride lipaseHomo sapiens (human)
monoacylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of endocannabinoid signaling pathwayMonoglyceride lipaseHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
regulation of embryonic developmentHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IILysyl oxidase homolog 2Homo sapiens (human)
response to hypoxiaLysyl oxidase homolog 2Homo sapiens (human)
epithelial to mesenchymal transitionLysyl oxidase homolog 2Homo sapiens (human)
endothelial cell proliferationLysyl oxidase homolog 2Homo sapiens (human)
sprouting angiogenesisLysyl oxidase homolog 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysyl oxidase homolog 2Homo sapiens (human)
peptidyl-lysine oxidationLysyl oxidase homolog 2Homo sapiens (human)
collagen fibril organizationLysyl oxidase homolog 2Homo sapiens (human)
positive regulation of chondrocyte differentiationLysyl oxidase homolog 2Homo sapiens (human)
protein modification processLysyl oxidase homolog 2Homo sapiens (human)
endothelial cell migrationLysyl oxidase homolog 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionLysyl oxidase homolog 2Homo sapiens (human)
response to copper ionLysyl oxidase homolog 2Homo sapiens (human)
heterochromatin organizationLysyl oxidase homolog 2Homo sapiens (human)
negative regulation of stem cell population maintenanceLysyl oxidase homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (279)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
retinal dehydrogenase activityRetinal dehydrogenase 1Homo sapiens (human)
aldehyde dehydrogenase (NAD+) activityRetinal dehydrogenase 1Homo sapiens (human)
GTPase activator activityRetinal dehydrogenase 1Homo sapiens (human)
androgen bindingRetinal dehydrogenase 1Homo sapiens (human)
protein bindingRetinal dehydrogenase 1Homo sapiens (human)
aminobutyraldehyde dehydrogenase activityRetinal dehydrogenase 1Homo sapiens (human)
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activityRetinal dehydrogenase 1Homo sapiens (human)
NAD bindingRetinal dehydrogenase 1Homo sapiens (human)
3-deoxyglucosone dehydrogenase activityRetinal dehydrogenase 1Homo sapiens (human)
benzaldehyde dehydrogenase (NAD+) activityRetinal dehydrogenase 1Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
aldehyde dehydrogenase (NAD+) activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
aldehyde dehydrogenase [NAD(P)+] activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
phenylacetaldehyde dehydrogenase activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
electron transfer activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
nitroglycerin reductase activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
NAD bindingAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
carboxylesterase activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
AMP bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose 1,6-bisphosphate 1-phosphatase activityFructose-1,6-bisphosphatase 1Homo sapiens (human)
identical protein bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
metal ion bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
monosaccharide bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
interleukin-8 receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 2Homo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 3 Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 3 Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein-lysine 6-oxidase activityProtein-lysine 6-oxidaseHomo sapiens (human)
copper ion bindingProtein-lysine 6-oxidaseHomo sapiens (human)
protein bindingProtein-lysine 6-oxidaseHomo sapiens (human)
collagen bindingProtein-lysine 6-oxidaseHomo sapiens (human)
small molecule bindingProtein-lysine 6-oxidaseHomo sapiens (human)
molecular adaptor activityProtein-lysine 6-oxidaseHomo sapiens (human)
transcription cis-regulatory region bindingLysine-specific demethylase 5AHomo sapiens (human)
DNA bindingLysine-specific demethylase 5AHomo sapiens (human)
transcription coactivator activityLysine-specific demethylase 5AHomo sapiens (human)
enzyme inhibitor activityLysine-specific demethylase 5AHomo sapiens (human)
protein bindingLysine-specific demethylase 5AHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 5AHomo sapiens (human)
chromatin DNA bindingLysine-specific demethylase 5AHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 5AHomo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activityLysine-specific demethylase 5AHomo sapiens (human)
methylated histone bindingLysine-specific demethylase 5AHomo sapiens (human)
histone bindingLysine-specific demethylase 5AHomo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-C chemokine receptor type 2Homo sapiens (human)
CCR2 chemokine receptor bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 2 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 12 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 2Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 4Homo sapiens (human)
protein bindingC-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 4Homo sapiens (human)
virus receptor activityC-C chemokine receptor type 5Homo sapiens (human)
actin bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
protein bindingC-C chemokine receptor type 5Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 5Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylserine bindingGasdermin-DHomo sapiens (human)
protein bindingGasdermin-DHomo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingGasdermin-DHomo sapiens (human)
wide pore channel activityGasdermin-DHomo sapiens (human)
phosphatidylinositol-4-phosphate bindingGasdermin-DHomo sapiens (human)
phosphatidic acid bindingGasdermin-DHomo sapiens (human)
cardiolipin bindingGasdermin-DHomo sapiens (human)
fibronectin bindingLysyl oxidase homolog 3Homo sapiens (human)
protein-lysine 6-oxidase activityLysyl oxidase homolog 3Homo sapiens (human)
copper ion bindingLysyl oxidase homolog 3Homo sapiens (human)
protein bindingLysyl oxidase homolog 3Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein-lysine 6-oxidase activityLysyl oxidase homolog 4Homo sapiens (human)
copper ion bindingLysyl oxidase homolog 4Homo sapiens (human)
protein bindingLysyl oxidase homolog 4Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
enzyme bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K56 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
lysophospholipase activityMonoglyceride lipaseHomo sapiens (human)
protein bindingMonoglyceride lipaseHomo sapiens (human)
protein homodimerization activityMonoglyceride lipaseHomo sapiens (human)
acylglycerol lipase activityMonoglyceride lipaseHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein-lysine 6-oxidase activityLysyl oxidase homolog 2Homo sapiens (human)
copper ion bindingLysyl oxidase homolog 2Homo sapiens (human)
calcium ion bindingLysyl oxidase homolog 2Homo sapiens (human)
protein bindingLysyl oxidase homolog 2Homo sapiens (human)
oligosaccharide bindingLysyl oxidase homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (167)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmRetinal dehydrogenase 1Homo sapiens (human)
cytosolRetinal dehydrogenase 1Homo sapiens (human)
axonRetinal dehydrogenase 1Homo sapiens (human)
synapseRetinal dehydrogenase 1Homo sapiens (human)
extracellular exosomeRetinal dehydrogenase 1Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrionAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial matrixAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
extracellular exosomeAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
nucleusFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytoplasmFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytosolFructose-1,6-bisphosphatase 1Homo sapiens (human)
extracellular exosomeFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytoplasmFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytosolFructose-1,6-bisphosphatase 1Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
nucleoplasmC-X-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 2Homo sapiens (human)
microtubule cytoskeletonC-X-C chemokine receptor type 2Homo sapiens (human)
membraneC-X-C chemokine receptor type 2Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 2Homo sapiens (human)
mast cell granuleC-X-C chemokine receptor type 2Homo sapiens (human)
mitotic spindleC-X-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
nuclear envelopeMitogen-activated protein kinase 3 Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 3 Homo sapiens (human)
early endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
late endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 3 Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 3 Homo sapiens (human)
cytosolMitogen-activated protein kinase 3 Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 3 Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 3 Homo sapiens (human)
caveolaMitogen-activated protein kinase 3 Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 3 Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 3 Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 3 Homo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
extracellular regionProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular spaceProtein-lysine 6-oxidaseHomo sapiens (human)
collagen trimerProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular spaceProtein-lysine 6-oxidaseHomo sapiens (human)
collagen-containing extracellular matrixProtein-lysine 6-oxidaseHomo sapiens (human)
nucleusLysine-specific demethylase 5AHomo sapiens (human)
nucleoplasmLysine-specific demethylase 5AHomo sapiens (human)
nucleolusLysine-specific demethylase 5AHomo sapiens (human)
nucleusLysine-specific demethylase 5AHomo sapiens (human)
chromatinLysine-specific demethylase 5AHomo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
fibrillar centerC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytosolC-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
membraneC-C chemokine receptor type 2Homo sapiens (human)
dendriteC-C chemokine receptor type 2Homo sapiens (human)
neuronal cell bodyC-C chemokine receptor type 2Homo sapiens (human)
perikaryonC-C chemokine receptor type 2Homo sapiens (human)
perinuclear region of cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membraneC-C chemokine receptor type 4Homo sapiens (human)
neuronal cell bodyC-C chemokine receptor type 4Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 4Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
endosomeC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cytoplasmC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneGasdermin-DHomo sapiens (human)
membraneGasdermin-DHomo sapiens (human)
extracellular regionGasdermin-DHomo sapiens (human)
extracellular spaceGasdermin-DHomo sapiens (human)
nucleoplasmGasdermin-DHomo sapiens (human)
cytosolGasdermin-DHomo sapiens (human)
plasma membraneGasdermin-DHomo sapiens (human)
mitochondrial membraneGasdermin-DHomo sapiens (human)
specific granule lumenGasdermin-DHomo sapiens (human)
tertiary granule lumenGasdermin-DHomo sapiens (human)
ficolin-1-rich granule lumenGasdermin-DHomo sapiens (human)
NLRP3 inflammasome complexGasdermin-DHomo sapiens (human)
extracellular regionLysyl oxidase homolog 3Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 3Homo sapiens (human)
nucleusLysyl oxidase homolog 3Homo sapiens (human)
cytoplasmLysyl oxidase homolog 3Homo sapiens (human)
membraneLysyl oxidase homolog 3Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 3Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 3Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytosolNACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
membraneLysyl oxidase homolog 4Homo sapiens (human)
extracellular exosomeLysyl oxidase homolog 4Homo sapiens (human)
receptor complexLysyl oxidase homolog 4Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 4Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 4Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nuclear speckHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
endoplasmic reticulum membraneMonoglyceride lipaseHomo sapiens (human)
cytosolMonoglyceride lipaseHomo sapiens (human)
plasma membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nuclear bodyHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 2Homo sapiens (human)
basement membraneLysyl oxidase homolog 2Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 2Homo sapiens (human)
nucleusLysyl oxidase homolog 2Homo sapiens (human)
nucleoplasmLysyl oxidase homolog 2Homo sapiens (human)
endoplasmic reticulumLysyl oxidase homolog 2Homo sapiens (human)
membraneLysyl oxidase homolog 2Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 2Homo sapiens (human)
chromatinLysyl oxidase homolog 2Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 2Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (343)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1525287Inhibition of GSDMD in mouse monocyte/macrophages assessed as inhibition of pyroptosis in presence of Cu2+2019MedChemComm, May-01, Volume: 10, Issue:5
Gasdermin D (GSDMD) as a new target for the treatment of infection.
AID45885Antiviral activity against HIV-1ADA in CEM-SS cells using monocyte/macrophage cultures1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.
AID1884048Inhibition of SARS-CoV-2 papain-like protease expressed in Escherichia coli BL21(DE3) using Dabcy-FTLKGGAPTKVTE-Edans-NH2 as substrate by multilabel plate reader analysis2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1743086Antigiardial activity against Giardia lamblia GS/H7 trophozoites incubated for 3 days by microscopic method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1762210Inhibition of ALDH1A1 (unknown origin)2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Development of new disulfiram analogues as ALDH1a1-selective inhibitors.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1313262Inhibition of chymotrypsin like activity of 20S proteasome (unknown origin) using suc-leu-leu-val-tyr-AMC as substrate at 10 uM after 40 mins in presence of iron by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Cupriphilic compounds to aid in proteasome inhibition.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1391185Antibacterial activity against Salmonella typhi Ty2 after 20 hrs by Todd Hewitt broth broth microdilution method2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1899611Inhibition of SARS-CoV-2 3CL protease using Dabcyl-KNSTLQSGLRKE-Edan as substrate incubated for 30 mins and measured by FRET assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
AID1391181Antibacterial activity against Escherichia coli DC10B after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1654819Selectivity ratio of IC50 for inhibition of human liver FBPase C116S mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1391170Antibacterial activity against Yersinia pestis Kuma D7 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1743058Inhibition of Giardia lamblia carbamate Kinase preincubated for 15 mins followed by ADP and carbamate phosphate addition and measured after 20 mins by ATPLite reagent based luminescence assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1822759Inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase transfected in Escherichia coli BL21 (DE3) at 50 uM incubated for 3 mins in presence of NADH by spectrophotometric analysis relative to control2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1391190Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus COL assessed as vancomycin MIC after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1654825Selectivity ratio of IC50 for inhibition of human liver FBPase N125A mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1391187Antibacterial activity against Shigella dysenteriae Newcastle 1934 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1399356Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1391157Antibacterial activity against vancomycin-intermediate resistant Staphylococcus aureus AR-217 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391195Synergistic antibacterial activity against vancomycin-intermediate resistant Staphylococcus aureus AR-217 assessed as fractional inhibitory concentration in presence of vancomycin after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1692494Inhibition of SARS-CoV2 3C-like protease expressed in Escherichia coli BL21 (DE3) cells using Mca-AVLQSGFR-K(Dnp)K as substrate by fluorescence method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
COVID-19: Drug Targets and Potential Treatments.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1391201Synergistic antibacterial activity against vancomycin-intermediate resistant Staphylococcus epidermidis NRS53 assessed as fractional inhibitory concentration in presence of vancomycin after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1399355Inhibition of recombinant human LOXL3 expressed in CHO cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID477887Inhibition of wild type human recombinant His-BCA2 autoubiquitination expressed in Escherichia coli at 5 uM after 30 mins by Western blotting in presence of human recombinant E2 UbcH5b2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID1399349Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1391175Antibacterial activity against Rhodococcus erythropolis SK121 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1654826Hypoglycemic activity in 12 hrs fasted ICR mouse assessed as reduction in blood glucose level at 100 mg/kg, po measured after 4 hrs by glucometric method2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1184068Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1374913Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from 3 types of Cys9-type Zn fingers at >50 uM after 1 hr by circular2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID589102Mechanism based inhibition of human cytochrome P450 2E12005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1374916Induction of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) protein unfolding at 100 uM by circular dichroism analysis2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID477882Antiproliferative activity against human MDA-MB-231 cells expressing BCA2 and ERalpha after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID1391192Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus COL assessed as fractional inhibitory concentration in presence of vancomycin after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID441697Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate by liquid scintillation counting2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID1623304Cytotoxicity against patient derived GSC after 96 hrs by CellTiter-Glo assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Recent advances in the discovery of small molecules targeting glioblastoma.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1654816Inhibition of human liver FBPase C281S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1654824Inhibition of human liver FBPase C128S mutant expressed in Escherichia coli BL21 (DE3) at 1000 uM using FBP as substrate incubated for 5 mins by malachite green dye based assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1762211Inhibition of ALDH2 (unknown origin)2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Development of new disulfiram analogues as ALDH1a1-selective inhibitors.
AID1399354Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1374895Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1654820Selectivity ratio of IC50 for inhibition of human liver FBPase C128S mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1374901Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID441696Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate at 10 uM by liquid scintillation counting2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID1391177Antibacterial activity against Brucella neotomae 5K33 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID477885Antiproliferative activity against human MCF7 cells expressing BCA2 and estrogen receptor at IC50 concentration after 5 days by MTT assay in presence of 75 uM to 600 nM zinc chloride2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1391167Antibacterial activity against Bacillus anthracis Weybridge after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID89654Inhibition of HIV-1 replication in human T-cell by using XTT assay; Inactive1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors.
AID1391166Antibacterial activity against Bacillus anthracis UM23-1 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391173Antibacterial activity against Listeria monocytogenes Gibson after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID477881Antiproliferative activity against BCA2 and ER deficient human MDA-MB-231 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID1391178Antibacterial activity against Burkholderia multivorans CF2 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1374905Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 2.5 to 100 uM after 500 to 3500 secs by FluoZi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1399353Inhibition of recombinant human LOX expressed in HEK293 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1391200Synergistic antibacterial activity against vancomycin-intermediate resistant Staphylococcus epidermidis NRS53 after 20 hrs in presence of vancomycin by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1184075Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID441792Selectivity ratio for human MGL activity to human recombinant FAAH2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1845236Inhibition of SARS-CoV-2 MPro2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID477884Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID1363916Inhibition of recombinant human N-terminal His6-tagged and C-terminal Strep-tagged MAGL expressed in Escherichia coli Rosetta using [3H]2-OG as substrate after 10 mins by liquid scintillation counting method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
AID1654810Inhibition of human liver FBPase C38S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1391197Synergistic antibacterial activity against vancomycin-resistant Staphylococcus aureus HIP14300 after 20 hrs in presence of vancomycin by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391171Antibacterial activity against Bacillus cereus Gibson 971 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1374912Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at >50 uM after 1 hr by circular dichroism analys2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374911Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at >50 uM after 1 hr by circular dichroism analys2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID477894Inhibition of ALDH1 in human K562 cells at 15 uM after 45 mins by flow cytometry based method relative to bodipy-aminoacetaldehyde2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1743059Antigiardial activity against Giardia lamblia incubated for 48 hrs by ATPLite reagent based luminescence assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1654807Inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1718095Inhibition of SARS-CoV papain-like protease using Ub-7-amino-4-trifluoro-methylcoumarin as substrate incubated for 3 mins by fluorescence method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1391198Synergistic antibacterial activity against vancomycin-resistant Staphylococcus aureus HIP14300 assessed as fractional inhibitory concentration in presence of vancomycin after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID589101Mechanism based inhibition of human cytochrome P450 2E12005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1391202Antibacterial activity against vancomycin-intermediate resistant Staphylococcus epidermidis NRS53 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID441699Inhibition of recombinant rat ALDH activity in liver mitochondria2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID477893Cytotoxicity against human K562 cells expressing ALDH1 at 15 uM after 45 mins by flow cytometry based method2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1506822Inhibition of JARID1A PHD finger domain (unknown origin)2017European journal of medicinal chemistry, Aug-18, Volume: 136Methyllysine binding domains: Structural insight and small molecule probe development.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1654827Hypoglycemic activity in 12 hrs fasted ICR mouse assessed as reduction in blood glucose AUC (0 to 8 hrs) at 100 mg/kg, po by glucometric method relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1313260Inhibition of chymotrypsin like activity of 20S proteasome (unknown origin) using suc-leu-leu-val-tyr-AMC as substrate at 10 uM after 40 mins in presence of nickel by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Cupriphilic compounds to aid in proteasome inhibition.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1374902Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1391184Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1654811Inhibition of human liver FBPase C92S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1374898Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID441698Inhibition of human recombinant FAAH-maltose binding protein2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID45377Antiviral activity against HIV-1ADA in CEM-SS cells using monocyte/macrophage cultures; I = No antiviral activity1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.
AID1391189Antibacterial activity against Yersinia pseudotuberculosis P61 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391164Antibacterial activity against Bacillus anthracis Ames 35 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID477888Inhibition of recombinant RING-E3 ligase Mdm2 autoubiquitination at 5 to 50 uM after 30 mins by Western blotting in presence of human recombinant E2 UbcH5b2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID1525286Inhibition of GSDMD in human monocyte/macrophages assessed as inhibition of pyroptosis in presence of Cu2+2019MedChemComm, May-01, Volume: 10, Issue:5
Gasdermin D (GSDMD) as a new target for the treatment of infection.
AID1391179Antibacterial activity against Burkholderia cepacia UCB 717 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1313263Inhibition of chymotrypsin like activity of 20S proteasome (unknown origin) using suc-leu-leu-val-tyr-AMC as substrate at 10 uM after 40 mins in presence of zinc by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Cupriphilic compounds to aid in proteasome inhibition.
AID1654817Selectivity ratio of IC50 for inhibition of human liver FBPase C38S mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1374896Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1654822Selectivity ratio of IC50 for inhibition of human liver FBPase C183S mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1391199Synergistic antibacterial activity against vancomycin-intermediate resistant Staphylococcus epidermidis NRS53 assessed as vancomycin MIC after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1399352Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1374915Induction of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) protein unfolding at 100 uM by circular dichroism analysis2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1391191Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus COL in presence of vancomycin after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1743085Antigiardial activity against Giardia lamblia 713M3 trophozoites incubated for 3 days by microscopic method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1391204Elimination half life in pooled rat liver microsomes in presence of NADPH by LC-MS/MS analysis2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID589103Mechanism based inhibition of human cytochrome P450 2E12005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1654818Selectivity ratio of IC50 for inhibition of human liver FBPase C92S mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1391188Antibacterial activity against Vibrio cholerae TS D4 after 20 hrs by Todd Hewitt broth broth microdilution method2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1391194Synergistic antibacterial activity against vancomycin-intermediate resistant Staphylococcus aureus AR-217 after 20 hrs in presence of vancomycin by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID89002Compound was tested for binding of HIV-1 to CEM-ss cells; NI = No inhibition1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.
AID1391186Antibacterial activity against Yersinia enterocolitica WA-314 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391183Antibacterial activity against Proteus mirabilis HM-752 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID161899Compound was tested for effects on HIV-1 protease; NI = No inhibition1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1391182Antibacterial activity against Klebsiella pneumoniae 700603 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1374900Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1810186Inhibition of SARS coronavirus 2 3 main viral protease 3-chymotrypsin-like activity expressed in Escherichia coli using Dabcyl-VNSTLQSGLRK(FAM)MA as substrate measured by fluorescence intensity assay2022ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1
Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID477880Antiproliferative activity against human MCF7 cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID1391156Antibacterial activity against methicillin-resistant Staphylococcus aureus COL after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1654823Selectivity ratio of IC50 for inhibition of human liver FBPase C281S mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1399351Inhibition of recombinant human LOXL3 expressed in CHO cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1391176Antibacterial activity against Acinetobacter baumannii AB5075 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1703767Inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3) using FBP as substrate by malachite green dye based assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.
AID1374914Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from from 3 types of Cys9-type Zn fingers at >50 uM after 1 hr by cir2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374899Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1391161Antibacterial activity against Streptococcus agalactiae SGBS005 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1374906Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 2.5 to 100 uM after 500 to 3500 secs by FluoZi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1313261Inhibition of chymotrypsin like activity of 20S proteasome (unknown origin) using suc-leu-leu-val-tyr-AMC as substrate at 10 uM after 40 mins in presence of calcium by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Cupriphilic compounds to aid in proteasome inhibition.
AID1899613Inhibition of SARS-CoV 3CL protease using Dabcyl-KNSTLQSGLRKE-Edan as substrate incubated for 30 mins and measured by FRET assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
AID45375Antiviral activity against HIV-1 in CEM-SS cells using XXT assay; I = No antiviral activity1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID650644Inhibition of Saccharomyces cerevisiae alcohol dehydrogenase measured every 5 mins for 2 hrs by spectrophotometry2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Tea catechins and flavonoids from the leaves of Camellia sinensis inhibit yeast alcohol dehydrogenase.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1374897Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1654815Inhibition of human liver FBPase C183S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1391172Antibacterial activity against Corynebacterium striatum FS-1 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391205Intrinsic clearance in pooled rat liver microsomes measured up to 60 mins in presence of NADPH by LC-MS/MS analysis2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1718096Inhibition of MERS-CoV papain-like protease using Ub-7-amino-4-trifluoro-methylcoumarin as substrate incubated for 3 mins by fluorescence method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1391203Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1391160Antibacterial activity against Streptococcus pyogenes H293 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1654812Inhibition of human liver FBPase C116S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1654814Inhibition of human liver FBPase C179S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID89802Inhibition of HIV-1 replication in a proliferating human T-cell line assayed using an XTT assay.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1654813Inhibition of human liver FBPase C128S mutant expressed in Escherichia coli BL21 (DE3) using FBP as substrate incubated for 5 mins by malachite green dye based assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1313259Inhibition of chymotrypsin like activity of 20S proteasome (unknown origin) using suc-leu-leu-val-tyr-AMC as substrate at 10 uM after 40 mins in presence of 1 uM copper by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Cupriphilic compounds to aid in proteasome inhibition.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1391180Antibacterial activity against Citrobacter freundii 4_7_47CFAA after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1759582Inhibition of NLRP3 in mouse J774A.1 cells infected with FLA-ST assessed as inhibition of LPS- induced IL-1beta production by ELISA2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1391193Synergistic antibacterial activity against vancomycin-intermediate resistant Staphylococcus aureus AR-217 assessed as vancomycin MIC after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1654830Solubility of the compound in water2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1391206Antibacterial activity against methicillin-resistant Staphylococcus aureus2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1391163Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391196Synergistic antibacterial activity against vancomycin-resistant Staphylococcus aureus HIP14300 assessed as vancomycin MIC after 20 hrs by checkerboard microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID374033Antimicrobial activity against Mycobacterium tuberculosis H37Rv2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.
AID1391168Antibacterial activity against Francisella tularensis Utah 112 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1893103Inhibition of human FBPase expressed Escherichia coli BL21 in by malachite green dye based spectrophotometry2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
AID1391159Antibacterial activity against vancomycin-intermediate resistant Staphylococcus epidermidis NRS6 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID477886Inhibition of wild type human recombinant His-BCA2 autoubiquitination expressed in Escherichia coli at 50 uM after 30 mins by Western blotting in presence of human recombinant E2 UbcH5b2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID1391165Antibacterial activity against Bacillus anthracis Sterne 34F2 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID482138Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1654821Selectivity ratio of IC50 for inhibition of human liver FBPase C179S mutant expressed in Escherichia coli BL21 (DE3) to IC50 for inhibition of wild-type full-length human liver FBPase expressed in Escherichia coli BL21 (DE3)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
AID1399350Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1391169Antibacterial activity against Yersinia pestis Kim D2 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1391162Antibacterial activity against Streptococcus pneumoniae TCH8431 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1391174Antibacterial activity against Micrococcus luteus SK58 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID477883Antiproliferative activity against human T47D cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID45884Antiviral activity against HIV-1 in CEM-SS cells using XXT assay1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.
AID1762212Inhibition of ALDH1A1 (unknown origin) in presence of dithiothreitol2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Development of new disulfiram analogues as ALDH1a1-selective inhibitors.
AID1391158Antibacterial activity against vancomycin-resistant Staphylococcus aureus HIP14300 after 20 hrs by broth microdilution assay2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
Disulfiram-based disulfides as narrow-spectrum antibacterial agents.
AID1845234Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) using Mca-AVLQ SGFR-K(Dnp)K as substrate by EnVision multimode plate reader analysis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID200145Compound was tested for the effect on HIV-1 Reverse Transcriptase; NI = No inhibition1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1801388Inhibition Assay from Article 10.1111/cbdd.12572: \\Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.\\2015Chemical biology & drug design, Nov, Volume: 86, Issue:5
Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1803933high-throughput activity assay from Article 10.1038/s41586-020-2223-y: \\Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors \\2020Nature, 06, Volume: 582, Issue:7811
Structure of M
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1345951Rat aldehyde dehydrogenase 2 family member (1.-.-.- Oxidoreductases)2000Biochemical pharmacology, Oct-01, Volume: 60, Issue:7
Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,482)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902009 (57.70)18.7374
1990's396 (11.37)18.2507
2000's305 (8.76)29.6817
2010's492 (14.13)24.3611
2020's280 (8.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 97.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index97.76 (24.57)
Research Supply Index8.28 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index182.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (97.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials175 (4.63%)5.53%
Reviews315 (8.34%)6.00%
Case Studies330 (8.74%)4.05%
Observational4 (0.11%)0.25%
Other2,952 (78.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (52)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Patients With Treatment-Refractory Sarcomas [NCT05210374]Phase 124 participants (Anticipated)Interventional2023-03-09Recruiting
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme [NCT03363659]Phase 215 participants (Actual)Interventional2018-03-28Terminated(stopped due to Investigator decision)
Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer [NCT03323346]Phase 2150 participants (Anticipated)Interventional2017-09-29Recruiting
Effectiveness of Disulfiram for Treating Cocaine Dependence in Individuals With Different Dopamine Beta Hydroxylase (DBH) Genes [NCT00149630]Phase 293 participants (Actual)Interventional2005-01-31Completed
DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19 [NCT04485130]Phase 211 participants (Actual)Interventional2021-08-18Terminated(stopped due to Low COVID case numbers, competing COVID treatments available)
Body Weight Response With Disulfiram in Humans. Concept Testing Study [NCT05162001]Early Phase 110 participants (Anticipated)Interventional2021-11-21Enrolling by invitation
Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder [NCT02735577]Phase 47 participants (Actual)Interventional2016-03-31Completed
Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts [NCT02134002]Phase 40 participants (Actual)Interventional2014-06-30Withdrawn(stopped due to Too selective recrutment criteria, none eligible patients)
Promoting Medications for Alcohol Use Disorder on the General Medicine Service at Yale New Haven Hospital: a Pilot Study [NCT04287790]67 participants (Actual)Observational2020-01-01Terminated(stopped due to COVID-19 disrupted recruitment)
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma [NCT03034135]Phase 223 participants (Actual)Interventional2017-03-09Completed
Clinical Study of Disulfiram Combined With Cisplatin in the Treatment of Advanced Gastric Cancer [NCT05667415]40 participants (Anticipated)Interventional2023-06-01Not yet recruiting
Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder [NCT04502589]Phase 1/Phase 24 participants (Actual)Interventional2020-10-15Completed
A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine [NCT03714555]Phase 21 participants (Actual)Interventional2019-10-17Terminated(stopped due to Study was closed due to low subject enrollment at site.)
"Disulfiram (Antabuse): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease" [NCT03891667]Phase 1/Phase 211 participants (Actual)Interventional2019-07-31Completed
DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial [NCT02678975]Phase 2/Phase 388 participants (Actual)Interventional2017-01-31Completed
Open-Label Pilot Study of Disulfiram for Methamphetamine Dependence [NCT00731133]Phase 1/Phase 215 participants (Actual)Interventional2008-08-31Completed
Disulfiram for Cocaine Abuse in Buprenorphine Treatment [NCT00913484]Phase 2177 participants (Actual)Interventional2000-10-31Completed
Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver [NCT00742911]Phase 121 participants (Actual)Interventional2008-07-31Completed
Disulfiram for Cocaine Abuse [NCT00395850]Phase 2118 participants (Actual)Interventional2007-04-30Completed
[NCT02101008]Phase 212 participants (Actual)Interventional2010-03-31Completed
Maximizing the Efficacy of Cognitive Behavioral Therapy With Medication and Contingency Management [NCT00350870]Phase 1181 participants (Actual)Interventional2005-04-30Completed
A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma [NCT01907165]Early Phase 121 participants (Actual)Interventional2013-10-10Completed
Phase II Study of Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. [NCT04265274]Phase 20 participants (Actual)Interventional2020-01-01Withdrawn(stopped due to Poor acrual)
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (Phase 1b) [NCT00571116]Phase 19 participants (Actual)Interventional2006-09-30Terminated(stopped due to Halted because of slow accrual and lack of study funding)
A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19 [NCT04594343]Phase 2140 participants (Actual)Interventional2020-11-20Completed
Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers [NCT00580827]126 participants (Actual)Interventional2003-09-30Completed
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma [NCT02770378]Phase 1/Phase 210 participants (Actual)Interventional2016-11-30Completed
Antabuse in Severe Alcoholism: an Open Controlled Study [NCT00431262]Phase 460 participants Interventional2007-02-28Recruiting
Phase Four Randomized, Multicentre, Open-Label, Comparative Trial Of Disulfiram, Nalterexone And Acamprosate In The Treatment Of Alcohol Dependence [NCT00435435]Phase 4243 participants Interventional2000-09-30Completed
Disulfiram Interactions With HIV Medications: Clinical Implications [NCT00878306]Phase 140 participants (Actual)Interventional2008-11-30Completed
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer [NCT02963051]Phase 19 participants (Actual)Interventional2017-07-11Terminated(stopped due to Study stopped due to lack of efficacy.)
Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram [NCT03212599]17 participants (Actual)Observational2013-05-31Completed
Laboratory Models of Cocaine Self-administration [NCT00729300]Phase 1/Phase 252 participants (Actual)Interventional2006-04-30Completed
Interactions Between IV Cocaine and Ethanol and Oral Disulfiram [NCT00094289]Phase 116 participants Interventional2004-08-31Active, not recruiting
Two Medications, Disulfiram and Naltrexone, in the Treatment of Patients With Both Cocaine and Alcohol Dependence [NCT00142844]Phase 2208 participants (Actual)Interventional1999-09-30Completed
A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma [NCT04521335]Phase 12 participants (Actual)Interventional2021-05-21Terminated(stopped due to Closed at PI's Request)
Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma [NCT03151772]Early Phase 13 participants (Actual)Interventional2018-01-29Terminated(stopped due to Problems with including patients)
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study [NCT01944371]Phase 1/Phase 230 participants (Actual)Interventional2013-09-30Completed
Disulfiram for Cocaine Abuse in Methadone- Patients [NCT00218608]Phase 2158 participants (Actual)Interventional2001-04-30Completed
Evaluation of Disulfiram in Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy, Phase I/II [NCT00256230]Phase 1/Phase 27 participants (Actual)Interventional2002-01-31Completed
Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine [NCT00312819]Phase 2/Phase 360 participants (Anticipated)Interventional2006-03-31Completed
A PHASE II CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY OF DISULFIRAM/COPPER COMBINATION AS AN ADJUVANT AND CONCURRENT CHEMOTHERAPY IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORM [NCT01777919]Phase 232 participants (Anticipated)Interventional2017-01-31Not yet recruiting
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma [NCT02715609]Phase 1/Phase 235 participants (Actual)Interventional2016-06-15Active, not recruiting
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals [NCT01286259]16 participants (Actual)Interventional2011-01-31Completed
Expansion Cohort Study of Disulfiram and Chemotherapy in Pancreas Cancer Patients [NCT02671890]Phase 116 participants (Actual)Interventional2016-02-25Active, not recruiting
A Cross-over Randomized Control Trial to Evaluate the Retinaldehyde Dehydrogenase Inhibitor, Disulfiram, in Improving Retinal Sensitivity in Eyes Affected by Inherited Retinal Degeneration [NCT05626920]Phase 1/Phase 230 participants (Anticipated)Interventional2023-12-31Recruiting
A Multi-institutional Translational Clinical Trial of Disulfiram in Men With Recurrent Prostate Cancer as Evident by a Rising PSA [NCT01118741]19 participants (Actual)Interventional2010-05-31Completed
Disulfiram for Cocaine-Alcohol Abuse [NCT00000278]Phase 20 participants Interventional1994-09-30Completed
Depot Disulfiram for AIDS and ARC [NCT00002065]0 participants InterventionalCompleted
Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder [NCT00721526]Phase 441 participants (Actual)Interventional2009-08-31Completed
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART (DIVA): A Single Arm Clinical Trial [NCT03198559]Phase 1/Phase 22 participants (Actual)Interventional2017-08-08Terminated(stopped due to A re-evaluation of research risks to participants were greater than originally anticipated)
Phase II Study of Disulfiram and Cisplatin in Refractory TGCTs. [NCT03950830]Phase 212 participants (Actual)Interventional2019-05-14Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00149630 (2) [back to overview]Retention by Treatment Condition.
NCT00149630 (2) [back to overview]Urine Toxicology for Cocaine.
NCT00350870 (2) [back to overview]Change in Cocaine Use by Self Report
NCT00350870 (2) [back to overview]Change in Cocaine Use by Urine Toxicology Results
NCT00395850 (2) [back to overview]Retention
NCT00395850 (2) [back to overview]Cocaine Use Over Time
NCT00721526 (5) [back to overview]Percent Days Abstinent From Alcohol (Among Participants Observed at Week 16)
NCT00721526 (5) [back to overview]Categorical Abstinence (Intent-to-treat Sample)
NCT00721526 (5) [back to overview]Categorical Abstinence (Among Those Observed at Week 16)
NCT00721526 (5) [back to overview]Treatment Adherence
NCT00721526 (5) [back to overview]Percent Days Abstinent From Alcohol (Intent-to-treat Sample)
NCT00729300 (1) [back to overview]Cocaine Self-administration
NCT00731133 (2) [back to overview]Proportion of Amphetamine-positive Urine Samples
NCT00731133 (2) [back to overview]Side Effects Checklist
NCT01118741 (2) [back to overview]Clinical Response
NCT01118741 (2) [back to overview]Proportion of Subjects With a Demethylation Response at Each Dose Level
NCT01286259 (4) [back to overview]Impact of Two Weeks of Disulfiram, as Measured by the Fold Change in the Infectious Units Per Million Cells (IUPM) Between Baseline and Week 12
NCT01286259 (4) [back to overview]Number of Participants With Adverse Events
NCT01286259 (4) [back to overview]Number of Participants With Detectable Plasma HIV RNA
NCT01286259 (4) [back to overview]The Fold Change in Mean Levels of Viremia During and After Disulfiram Dosing as Compared to Baseline Levels
NCT01944371 (4) [back to overview]Cell-associated HIV RNA
NCT01944371 (4) [back to overview]Disufiram Pharmacokinetics
NCT01944371 (4) [back to overview]Proviral HIV DNA
NCT01944371 (4) [back to overview]Plasma HIV RNA
NCT02101008 (2) [back to overview]Overall Response Rate to Treatment of Melanoma With Disulfiram and Chelated Zinc
NCT02101008 (2) [back to overview]Progression Free Survival
NCT02735577 (1) [back to overview]Alcohol Use
NCT03034135 (6) [back to overview]Progression Free Survival
NCT03034135 (6) [back to overview]Median Duration of Overall Survival
NCT03034135 (6) [back to overview]Median Progression Free Survival
NCT03034135 (6) [back to overview]Number of Participants With Serious Adverse Events
NCT03034135 (6) [back to overview]Overall Survival
NCT03034135 (6) [back to overview]Objective Response Rate
NCT03363659 (2) [back to overview]Overall Survival
NCT03363659 (2) [back to overview]6 Months Progression Free Survival (PFS)
NCT03891667 (6) [back to overview]The Short Form (36) Health Survey (SF-36) Mental Component Summary (MCS)
NCT03891667 (6) [back to overview]Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
NCT03891667 (6) [back to overview]Fatigue Severity Scale (FSS)
NCT03891667 (6) [back to overview]Patient-Reported Outcomes Measurement Information System (PROMIS-29) Symptom Summary Score on Sleep Disturbance, Pain, Anxiety, Depression, and Low Energy/Fatigue (SPADE)
NCT03891667 (6) [back to overview]General Symptom Questionnaire (GSQ-30)- Assess Multisystemic Symptom Burden
NCT03891667 (6) [back to overview]The Short Form (36) Health Survey (SF-36) Physical Component Summary (PCS)
NCT04485130 (4) [back to overview]Change in COVID-19 Symptom Severity Score as Assessed by a 5-point Adapted Somatic Symptom Severity Score (SSS-8)
NCT04485130 (4) [back to overview]Virologic Impact of 5 Days of Disulfiram, as Measured by the Change in Copies of SARS-CoV-2 Virus Per mL Between Baseline and Day 31.
NCT04485130 (4) [back to overview]Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
NCT04485130 (4) [back to overview]Immunologic Impact of 5 Days of Disulfiram, as Measured by the Fold-change in Plasma Levels of Pro-inflammatory Cytokines (e.g, Interleukin 6, Interleukin 1-beta, Etc.).
NCT04502589 (3) [back to overview]Percent Heavy Drinking Days
NCT04502589 (3) [back to overview]Percent Abstinent Days
NCT04502589 (3) [back to overview]Change in Alcohol Craving

Retention by Treatment Condition.

Treatment retention for full 12 weeks of study. (NCT00149630)
Timeframe: 12 weeks

Intervention% of subjects who complete 12 wks study (Number)
Disulfiram77
Placebo87

[back to top]

Urine Toxicology for Cocaine.

(NCT00149630)
Timeframe: Thrice weekly, baseline through week 14.

Intervention% cocaine + urines over 2 week blocks (Mean)
Placebo CC84
Placebo CT/TT68
Disulfiram CC56
Disulfiram CT/TT67

[back to top]

Change in Cocaine Use by Self Report

Self-reports of substance use will be documented at each contact via the Substance Use Calendar. Similar to the Form-90 and the Time Line Follow-Back, which have been shown to be reliable and valid instruments for monitoring substance use and other outcomes in longitudinal studies202-204, the Substance Use Calendar allows a flexible, continuous evaluation of substance use on a daily basis. (NCT00350870)
Timeframe: 12 weeks

Interventionpercentage of days abstinent (Mean)
Placebo72.2
Disulfiram79.2
Placebo Plus Contingency Management91.1
Disulfiram Plus Contingency Management69.6

[back to top]

Change in Cocaine Use by Urine Toxicology Results

We will use the Roche onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepenes, and opioids. (NCT00350870)
Timeframe: 12 weeks

Interventionpercentage of negative urines (Mean)
Placebo17.9
Disulfiram30.1
Placebo Plus Contingency Management53
Disulfiram Plus Contingency Management42.6

[back to top]

Retention

(NCT00395850)
Timeframe: 14 weeks

InterventionWeeks (Mean)
Placebo8.3
Disulfiram 2509.0
Disulfiram 3756.4
Disulfiram 5008.3

[back to top]

Cocaine Use Over Time

Urine toxicology results (dichotomous: positive or negative) for the presence of cocaine/cocaine metabolite during the disulfiram phase of the study. The change in the probability of a cocaine positive urine sample per day was assessed for each dose compared with placebo and slopes for each dose condition were calculated from Repeated Measures Genearlized Linear Models on a Binomial distribution (thus a Repeated Measures Logistic Regression) (NCT00395850)
Timeframe: thrice weekly for 12 weeks

Interventionslope (change in prob of coc-pos utox/d) (Number)
Placebo0.01
Disulfiram 2500.007
Disulfiram 375-0.01
Disulfiram 5000.007

[back to top]

Percent Days Abstinent From Alcohol (Among Participants Observed at Week 16)

As measured by Timeline Followback (NCT00721526)
Timeframe: Weeks 13-16 (Last 4 weeks of treatment)

InterventionPercent (Mean)
Disulfiram Plus Lorazepam87.00

[back to top]

Categorical Abstinence (Intent-to-treat Sample)

As measured by timeline followback (NCT00721526)
Timeframe: Weeks 13-16 (Last 4 weeks of treatment)

InterventionParticipants (Count of Participants)
Disulfiram Plus Lorazepam18

[back to top]

Categorical Abstinence (Among Those Observed at Week 16)

As measured by timeline followback (NCT00721526)
Timeframe: Weeks 13-16 (Last 4 weeks of treatment)

InterventionParticipants (Count of Participants)
Disulfiram Plus Lorazepam18

[back to top]

Treatment Adherence

Completion of 16 weeks of disulfiram treatment (NCT00721526)
Timeframe: 16 weeks

InterventionParticipants (Count of Participants)
Disulfiram Plus Lorazepam15

[back to top]

Percent Days Abstinent From Alcohol (Intent-to-treat Sample)

As measured by Timeline Followback (NCT00721526)
Timeframe: Weeks 13-16 (Last 4 weeks of treatment)

Interventionpercentage of days abstinent (Mean)
Disulfiram Plus Lorazepam65.14

[back to top]

Cocaine Self-administration

The reinforcing effects of cocaine were determined using a self-administration procedure in which subjects choose to take previously sampled doses of cocaine or cash of increasing monetary value. The mean number of cocaine choices across each drug condition (i.e., placebo and disulfiram) is reported. (NCT00729300)
Timeframe: 4 days

Interventioncocaine choices/participant (Mean)
Placebo2.5
Disulfiram Treatment Group4.8

[back to top]

Proportion of Amphetamine-positive Urine Samples

the proportion of urine samples positive for amphetamine. Data were entered into a mixed model ANOVA in order to determine whether scores significantly changed over time. A slope and standard deviation describing this change over time were generated and used as our outcome measures. (NCT00731133)
Timeframe: thrice weekly for 6 weeks

Interventionproportion of urines positive for amphet (Least Squares Mean)
Disulfiram 250 mg0.3639

[back to top]

Side Effects Checklist

It consists of 25 items describing side effects specific to disulfiram alone or combined with alcohol or cocaine that are rated on a scale from 0 (not at all) to 4 (very much). Total scores range from 0 (minimum) to 100 (maximum). Data were entered into a mixed model ANOVA in order to determine whether scores significantly changed over time. A slope and standard deviation describing this change over time were generated and used as our outcome measures. (NCT00731133)
Timeframe: Weekly for six weeks

Interventionunits on a scale (Least Squares Mean)
Disulfiram 250 mg9.6515

[back to top]

Clinical Response

"To assess the clinical response measured by prostate specific antigen (PSA) progression at 6 months after treatment with the defined dose of disulfiram in prostate cancer (PCa) patients with evidence of biochemical relapse after local therapy. Reported as number of participants with PSA progression by 6 months.~Criteria used to assess: A rise in PSA noted at 6 months, greater than 50% over PSA value at baseline and > 2 ng/ml, above the nadir. The rise was confirmed by a second PSA value obtained at least 1 week from that reference value." (NCT01118741)
Timeframe: Up to 6 months

Interventionparticipants (Number)
Disulfiram Low Dose 250mg Dose5
Disulfiram High Dose 500mg Dose0

[back to top]

Proportion of Subjects With a Demethylation Response at Each Dose Level

For both of the doses explored (i.e. disulfiram 250 mg PO daily and 500 mg PO daily) the proportion of subjects with a demethylation response was computed. A demethylation response was defined as a >=10% decrease from baseline in global 5-methyl cytosine content as assessed from peripheral blood mononuclear cells. (NCT01118741)
Timeframe: 24 months

Interventionproportion of participants (Number)
Disulfiram Low Dose 250mg Dose.22
Disulfiram High Dose 500mg Dose.30

[back to top]

Impact of Two Weeks of Disulfiram, as Measured by the Fold Change in the Infectious Units Per Million Cells (IUPM) Between Baseline and Week 12

"The size of the latent reservoir from each participant was measured by limiting dilution co-culture assay and reported as infectious units per million cells (IUPM).This assay measures the frequency of peripheral blood cells from which replication-competent HIV can be grown. The assay was performed at a baseline visit (two weeks before dosing began) and week 12 (10 weeks after the last dose). The primary outcome was the fold-change in IUPM before and after disufiram." (NCT01286259)
Timeframe: 12 weeks

InterventionFold change in IUPM (Mean)
Intervention Arm1.16

[back to top]

Number of Participants With Adverse Events

The safety and tolerability of a two-week course of disulfiram was defined using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, August 2009). Details are available on the RSC website (http://rsc.tech-res.com/safetyandpharmacovigilance/). The number of adverse events and their grade was determined for each subject. (NCT01286259)
Timeframe: Two weeks

InterventionParticipants (Count of Participants)
Intervention Arm0

[back to top]

Number of Participants With Detectable Plasma HIV RNA

Plasma HIV RNA levels were measured weekly using a commercial assay. The number of participants who had a detectable viral load (> 50 copies RNA/mL) was determined. (NCT01286259)
Timeframe: Two weeks

InterventionParticipants (Count of Participants)
Intervention Arm1

[back to top]

The Fold Change in Mean Levels of Viremia During and After Disulfiram Dosing as Compared to Baseline Levels

Residual viremia was measured using a singe copy assay (SCA) in plasma samples obtained at enrollment, Days -14, -7, 0, 2, 4, 7, 9, 11, 14, 16, and 18, and at weeks 3, 4, 8 and 12. The level of residual viremia measured by SCA prior to disulfiram (Days 14, 17 and 0), during treatment (Days 1 to 14) and after dosing (Days 16 and 18) was modelled using negative binomial regression, and reported as the mean fold-change during and after disulfiram as compared to that during the baseline period. (NCT01286259)
Timeframe: Baseline to Day 18

InterventionFold change (Mean)
Intervention Arm1.5

[back to top]

Cell-associated HIV RNA

Fold change cell-associated HIV RNA in Total CD4 T-Cells. (NCT01944371)
Timeframe: Baseline and 3 days

InterventionFold change (Mean)
Disulfiram 500mg1.7
Disulfiram 1000mg1.9
Disulfiram 2000mg1.6

[back to top]

Disufiram Pharmacokinetics

Plasma concentrations of disulfiram were measured on dosing day 1 (hours 0, 2, and 6), day 2 (hour 0), and day 3 (hours 0, 2, and 6), as well as on postdosing days 4, 8, and 31. The area under the curve (AUC) levels over 72 hours was estimated. (NCT01944371)
Timeframe: 31 days

Interventionmg-hour/liter (Mean)
Disulfiram 500mg3,186
Disulfiram 1000mg8,386
Disulfiram 2000mg22,331

[back to top]

Proviral HIV DNA

Fold change in HIV DNA levels between Baseline and Day 30 (NCT01944371)
Timeframe: Baseline and 30 days

InterventionFold change (Mean)
Disulfiram 500mg1.07
Disulfiram 1000mg0.83
Disulfiram 2000mg0.91

[back to top]

Plasma HIV RNA

Fold change in plasma HIV RNA levels from baseline through day 3 (NCT01944371)
Timeframe: Baseline and 3 days

InterventionFold change (Mean)
Disulfiram 500mg1.50
Disulfiram 1000mg0.90
Disulfiram 2000mg1.22

[back to top]

Overall Response Rate to Treatment of Melanoma With Disulfiram and Chelated Zinc

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scanning of the chest, abdomen and pelvis, or PET/CT scanning.: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02101008)
Timeframe: Response to treatment will be measured by RECIST evaluation at disease assessment time-points from date of randomization until the date of first documented progression or death from any cause whichever came first (up to 15 months.)

Interventionparticipants (Number)
Disulfiram and Chelated Zinc0

[back to top]

Progression Free Survival

(NCT02101008)
Timeframe: Every 56 days - for up to two years

Interventiondays (Mean)
Disulfiram and Chelated Zinc51.8

[back to top]

Alcohol Use

Number of drinking days (NCT02735577)
Timeframe: 42 days

Interventiondays (Mean)
Disulfiram0

[back to top]

Progression Free Survival

Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months

Interventionpercentage of participants (Number)
DSF-Cu14

[back to top]

Median Duration of Overall Survival

Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months

Interventionmonths (Median)
DSF-Cu7.1

[back to top]

Median Progression Free Survival

Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months

Interventionmonths (Median)
DSF-Cu1.7

[back to top]

Number of Participants With Serious Adverse Events

Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months

InterventionParticipants (Count of Participants)
DSF-Cu2

[back to top]

Overall Survival

Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months

Interventionpercentage of participants (Number)
6 months12 months
DSF-Cu6135

[back to top]

Objective Response Rate

ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Complete responsePartial Response
DSF-Cu00

[back to top]

Overall Survival

Overall Survival will be assessed as a number of participants alive at 1 and 2 years. (NCT03363659)
Timeframe: 1 and 2 years

InterventionParticipants (Count of Participants)
1 Year2 Years
Open Label92

[back to top]

6 Months Progression Free Survival (PFS)

To determine 6 month PFS of patients with unmethylated glioblastoma treated with DSF-Cu in combination with concurrent radiation and temozolomide. This was assessed by the number of participants who did not have disease progression and were alive at 6 months. (NCT03363659)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Open Label1

[back to top]

The Short Form (36) Health Survey (SF-36) Mental Component Summary (MCS)

The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. The 8 scales are-vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning mental health. Each scale is directly transformed into a 0-100 scale, the lower the score the more disability and the higher the score the less disability. We calculate the Mental Component Summary (MCS) (representing physical functioning) which represent the items in the SF-36 representing physical functioning (Ware, 2000); as in the sub scales, lower scores indicate greater disability.. The norm-based estimate mean is 50 with a standard deviation of 10. We report the magnitude of the change in scores from baseline to week 10 (or the last observation carried forward (LOCF)); a positive change score indicates improvement. (NCT03891667)
Timeframe: Change will be assessed over a 10 week interval

InterventionScore on scale (LOCF minus baseline) (Mean)
8 Week Disulfiram11.544
4 Week Disulfiram13.771

[back to top]

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)

The Q-LES-Q - SF is a self-reported questionnaire, with 16 items evaluating overall enjoyment and satisfaction with physical health, mood, work, household and leisure activities, social and family relationships, daily functioning, sexual life, economic status, overall well-being and medications. Responses are scored on a 5-point scale, where higher scores indicate better enjoyment and satisfaction with life (possible range 14-70). Fourteen summated items create the total Q-LES-Q - SF score. Two last items, about medications and overall life satisfaction, are considered independently. Meaningful improvement on the Q-LES-Q to is a change score between baseline and week 10 (or last observation carried forward) of at least 6.8 points; 6.8 refers to the minimally clinical significant difference (MCID) where a score equal to or greater than 6.8 points represents an improved quality of file. We report # with meaningful improvement. (NCT03891667)
Timeframe: Change will be assessed over a 10 week interval

InterventionParticipants (Count of Participants)
8 Week Disulfiram2
4 Week Disulfiram2

[back to top]

Fatigue Severity Scale (FSS)

This is a psychometrically validated self-report measure of fatigue. This measure consists of 11 items inquiring about the severity of fatigue in different situations during the past week. Scores for each item range from 1 to 7, where 1 indicates strong disagreement and 7 strong agreement. Higher scores indicate higher levels of fatigue. A responder on the FSS is an individual whose FSS total score has decreased by 0.7 its when compared baseline to week 10 (or last observation carried forward); 0.7 refers to the minimally clinical significant difference (MCID) in change over time. We report the number of participants who reached a meaningful reduction in fatigue (equal or more than MCID). (NCT03891667)
Timeframe: Change will be assessed over a 10 week interval

InterventionParticipants (Count of Participants)
8 Week Disulfiram4
4 Week Disulfiram2

[back to top]

Patient-Reported Outcomes Measurement Information System (PROMIS-29) Symptom Summary Score on Sleep Disturbance, Pain, Anxiety, Depression, and Low Energy/Fatigue (SPADE)

The PROMIS-29 is a psychometrically validated 29 item self-report measure covering 7 domains. The questions are ranked on a 5-point Likert Scale. The composite score on 5 symptoms of the 7 domains is known as the SPADE summary score (sleep disturbance, pain, anxiety, depression, and low energy/fatigue); this represents the most common chronic symptoms in the general population. Each domain has 5 response options (e.g., 1=not at all to 5=very much), with scale scores ranging from 4 to 20 and higher scores indicating worse symptom severity. Using the scores from these 5 domains, we calculated the average score (SPADE score); the SPADE score ranges from 1 to 5 with higher scores indicating more symptom severity. We report the magnitude of the change in SPADE scores from baseline to week 10 (or the last observation carried forward (LOCF)); a negative change score indicates improvement. (NCT03891667)
Timeframe: Change will be assessed over a 10 week interval

InterventionScore on scale (LOCF minus baseline) (Mean)
8 Week Disulfiram-4.598
4 Week Disulfiram-1.282

[back to top]

General Symptom Questionnaire (GSQ-30)- Assess Multisystemic Symptom Burden

"This is a psychometrically validated 30 item self-report measure of symptom burden. The measure asks participants to rate how bothered they have been with a particular symptom over a 2-week time frame. Responses are made on 5-point Likert scale ranging from not at all to very much (scored 0-4); and the total score ranges from 0-120. Higher scores indicate more symptom severity. We report the magnitude of the score change (week 10 or last observation carried forward (LOCF)) minus the baseline score; a negative change score indicates improvement." (NCT03891667)
Timeframe: Change will be assessed over a 10 week interval

Interventionchange in score (LOCF minus baseline) (Mean)
8 Week Disulfiram-25.6
4 Week Disulfiram-5.6

[back to top]

The Short Form (36) Health Survey (SF-36) Physical Component Summary (PCS)

The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. The 8 scales are-vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning mental health. Each scale is directly transformed into a 0-100 scale, the lower the score the more disability and the higher the score the less disability. We calculate the Physical Component Summary (PCS) (representing physical functioning) which represent the items in the SF-36 representing physical functioning (Ware, 2000); as in the sub scales, lower scores indicate greater disability.The norm-based estimate has a mean of 50 and a standard deviation of 10. We report the magnitude of the score change from baseline to week 10 (or the last observation carried forward (LOCF)); positive change scores indicate improvement. (NCT03891667)
Timeframe: Change will be assessed over a 10 week interval

InterventionScore on scale (LOCF minus baseline) (Mean)
8 Week Disulfiram13.707
4 Week Disulfiram5.765

[back to top]

Change in COVID-19 Symptom Severity Score as Assessed by a 5-point Adapted Somatic Symptom Severity Score (SSS-8)

"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31

Interventionunits on a scale (Median)
Cohort 1: Disulfiram-2.60
Cohort 1: Placebo-2.14

[back to top]

Virologic Impact of 5 Days of Disulfiram, as Measured by the Change in Copies of SARS-CoV-2 Virus Per mL Between Baseline and Day 31.

Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31

Interventioncopies/mL (Mean)
Cohort 1: Disulfiram 1000 mg-20.89
Cohort 1: Placebo-20

[back to top] [back to top]

Immunologic Impact of 5 Days of Disulfiram, as Measured by the Fold-change in Plasma Levels of Pro-inflammatory Cytokines (e.g, Interleukin 6, Interleukin 1-beta, Etc.).

Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31

,
Interventionfold change (Median)
Change in IL-6 (pg/mL) Day 0 to 31Change in IL-1B (pg/mL) Day 0 to 31
Cohort 1: Disulfiram 100 mg-0.1186-0.1402
Cohort 1: Placebo-0.02150.0268

[back to top]

Percent Heavy Drinking Days

Participant will report the number of alcoholic drinks they consumed during the previous weeks period. Based on participant report, the percent of days the participant drank heavily will be calculated over the 8 week active treatment period. (NCT04502589)
Timeframe: End of treatment, Up to 8 weeks

Interventionpercentage of days (Mean)
Perampanel by Itself73.60
Perapanel With Disulfiram0

[back to top]

Percent Abstinent Days

Participant will report the number of alcoholic drinks they consumed during the previous weeks period. Participants will be accessed for the full 12 week titration plus treatment period. However, for the purposes of the study, the percent of days the participant was abstinent will be calculated and reported only for the 8 week active treatment period. (NCT04502589)
Timeframe: End of treatment, up to 12 weeks

InterventionPercentage of days (Mean)
Perampanel by Itself3.13
Perapanel With Disulfiram100

[back to top]

Change in Alcohol Craving

Alcohol craving will be assessed using the Alcohol Urge Questionnaire (AUG). The AUG is an 8-item survey asking participants to rate their craving for alcohol on a 1 to 7 scale. The answers are summed yielding a score ranging from 7 to 56 with higher scores indicated higher alcohol craving. (NCT04502589)
Timeframe: Baseline to end of treatment, up to 12 weeks

Interventionscore on a scale (Mean)
Perampanel by Itself4
Perapanel With Disulfiram-1

[back to top]